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ABSTRACT
The unraveling of the underlying genetic basis in diseases has accelerated rapidly as a 
result of dramatic advances in the field of molecular genetics, and will hopefully in due 
course lead to innovative, effective treatments for many human genetic diseases. 
Statistical genetics plays an important role in nearly every aspect of modern genetics, 
whether one is attempting to find genes responsible for rare monogenic disorders or 
complex genetic conditions, create a genomic map, or establish the interactions of 
inheritance and environment in the development of common diseases. Molecular genetic 
research is fundamentally important to the field of medicine and to the elucidation of the 
basic mechanisms of biological systems. In this thesis different applications of statistical 
methods have been used to explore the genetic component of bipolar disorder and related 
traits.
Here, 41 families affected with bipolar disorder have been ascertained from the isolated 
population of Finland, presuming that the presence of stronger genetic and 
environmental homogeneity in this population than in many other populations is an 
advantage in gene localization. A genome-wide scan was performed identifying possible 
genomic susceptibility regions for bipolar disorder. The strongest evidence of linkage 
was provided by a locus on 16p12 in the two-point analysis (Zmax = 3.4) and on 4q32 in 
the three-point analysis (Zmax = 3.6). Encouraging results were also observed on 
chromosomes 12q23 and Xq25 (lod score > 2.0). The latter locus was already identified 
in a previous study and hence, a denser marker map was constructed covering 13cM of 
the critical region. The earlier linkage was found in one extended pedigree displaying 
bipolar disorder in several generations. In order to test the general significance of this 
linkage finding, as well as to narrow down the linked area, the genome-wide scan family 
sample consisting of 40 additional families was utilized in this analysis. The X-
chromosomal linkage finding was replicated in the other pedigrees, however only with 
modest statistical significance. The linked region was consequently somewhat narrowed, 
and it was established in the genome-wide search that Xq25 represents the major linked 
region in the one extended family. 
In order to extract all possible information of the genome-wide scan performed, different 
statistical strategies were utilized to cluster and re-analyze the results and the study 
sample. In one line of study, the linkage results of all the available worldwide genome 
scans in bipolar disorder were re-analyzed in a meta-analysis. From this study it could be 
concluded that the strong linkage detected in the individual study samples could not be 
replicated when combining the linkage results from all studies worldwide. However, 
weaker linkage findings that seemed to be quite consistent across studies now stood out 
given the stronger statistical power.  
In a different type of study, the genotype data of our bipolar genome-wide 
scan and a genome-wide scan conducted in schizophrenia also using a 
Finnish study sample were combined. Instead of assessing linkage of the 
disease entities as defined in DSM-IV, shared traits of the two disorders 
such as psychotic and affective symptoms were examined. This study 
revealed a distinct locus for affective symptoms on chromosome 6p21 and 
a distinct locus for psychotic symptoms on chromosome 5q14. 
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BPD bipolar disorder  
BPD-I bipolar disorder, type I 
BPD-II bipolar disorder, type II 
BPD-NOS bipolar disorder, not otherwise specified 
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DSM diagnostic and statistical manual of 
mental disorders 
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GABA gamma-aminobutyric acid 
HHRR haplotype-based haplotype relative risk 
IBD identical by descent 
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L likelihood 
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lod logarithm of odds 
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MLS maximum likelihood score 
MRI magnetic resonance imaging 
MZ monozygotic 
n number 
NPL non-parametric linkage 
PET positron emission tomography 
PCR polymerase chain reaction 
RFLP restriction fragment length polymorphism 
RNA ribonucleic acid 
SNP single nucleotide polymorphism 
STRP short tandem repeat 
 polymorphism 
SZ schizophrenia 
SZ-AFF schizoaffective disorder 
TDT transmission disequilibrium test 
θ theta, recombination fraction 
VNTR variable number of tandem  repeats 
Z lod score 
Zmax maximum lod score 
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1. Introduction
Bipolar disorder is a severe mental disorder affecting approximately 1% of the 
worldwide population, and it seems to be equally frequent in both sexes and all 
ethnicities (1). Epidemiological studies, such as family, twin and adoption studies 
together with genome-wide scans and targeted DNA-studies indicate strong genetic 
predisposition in bipolar disorder. A strong genetic contribution to causation has been 
confirmed by both a large twin study, which estimated a heritability rate of about 85% 
(2), and a Danish population sample of several million, which reported a 13-fold 
increased risk in first-degree relatives (3).  
The process of identifying genes underlying mental disorders faces many difficulties due 
to complex patterns of inheritance, lack of diagnostic biological tests and strong 
confounding or interacting influence of environmental factors. Successful genetic studies 
of complex disorders like bipolar disorder will require very large samples drawn from 
diverse populations, and/or samples drawn from genetically isolated populations. The 
Finnish population originates from a limited number of founders and has remained 
relatively isolated, resulting in increased genetic homogeneity. In addition, the molecular 
information can be combined with exceptional genealogical data available only in a few 
countries offered by a well established church record system which dates back to 1640, 
containing detailed information on births, deaths, marriages and movements of the 
majority of the population. This provides excellent opportunities for special study 
designs for the identification not only of rare disease genes but also of major loci, which 
contribute to complex diseases. The genome-wide scan strategy using family material 
from the isolated Finnish population has already been a working strategy in identifying 
predisposing loci in several complex diseases such as multiple sclerosis, familial 
combined hyperlipidemia, type 2 diabetes, schizophrenia, distal interphalangeal arthritis 
and migraine with aura. Hence, it could hopefully also shed some light on the underlying 
biological factors in bipolar disorder. 
Through a variety of research approaches, including neuroscience studies, basic science 
approaches to brain and behavior, genetic investigations, epidemiological studies, and 
clinical research, better treatments are achieved, and hopefully ways to prevent and cure 
the illness will eventually be found.  
13
2. Review of literature 
2.1 The role of genetics in the etiology of disease 
In 1977 Frederick Sanger invented a new method for determining the order of nucleotide 
sequence of deoksiribonucleicacid (DNA) (4, 5) and subsequently the first human gene, 
Chorionic Somatomammotropin Hormone, was isolated and sequenced (6). Since then, the 
understanding of genes and their role in the etiology of disease has substantially increased, 
especially now that the draft sequence of the human genome is available (7, 8).  
The human genome consists of 46 chromosomes; 22 pairs of autosomal chromosomes 
and 2 sex chromosomes. These are built up of ~3.3 billion base pairs of DNA that in turn 
code for about 20,000 - 25,000 protein-coding genes, which is only twice as many as in 
the worm or fly (7, 8). Prior to the sequencing of the human genome, the number of 
genes in the human genome was predicted to be much greater (50 000 - 140 000). 
However, the draft sequence revealed that less than 5% of the genome is made up of 
coding regions, with differing gene densities between different chromosomal regions (7, 
8). Even though the human genome has a considerably lower number of genes than 
initially thought, the differences in the phenotypic complexity observed between the 
human and the fly or the worm is evident. In 1937, J.B.S Haldane was the first to suggest 
a theory concerning maximum genetic load of an organism, which illustrates that all 
genes have a certain low rate of mutations to a deleterious state. He argued that when the 
number of genes becomes too large, each zygote carries so many new delirious 
mutations that the population simply cannot be maintained. Hence, the lower number of 
genes might be compensated by combinatorial diversity generated at the levels of protein 
architecture, transcriptional and translational control, post-transcriptional modification of 
proteins, and post-transcriptional regulation. Extensive domain shuffling to increase or 
alter combinatorial diversity can provide an exponential increase in the ability to mediate 
protein-protein interactions without dramatically increasing the absolute size of the 
protein complement (9). The fact that nearly 40% of the genes seem to be alternatively 
spliced in the human genome (10) further suggests that these mechanisms of 
combinatorial diversity account for the greater phenotypic diversity found in humans 
compared with other species.  
The sequencing of the human genome has revolutionized the field of genetics. Among 
other things, it has enabled development of a genome-wide gene map covering 
previously and newly identified genes, and their internal order to each other. The next 
big challenge will be to identify function and interaction of the genes with each other, 
and to eventually identify their respective roles in different disorders. To date, over 1400 
genes have been linked to about 1200 Mendelian traits (11).  
The role of genetic factors in the etiology of disease varies considerably; some like cystic 
fibrosis are mostly genetically determined, while others, like post-accidental traumas 
might be almost entirely induced by environmental factors. Genetic disorders that are a 
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direct result of a mutation in one gene are called monogenic disorders, but are also 
known as Mendelian or single-gene disorders. These pose Mendelian patterns of 
inheritance; X-linked, autosomal recessive or dominant inheritance. The majority of the 
monogenic diseases are rare, the most common being red-green color blindness affecting 
approximately 8-10 % of most of the worldwide male population (12). In addition to the 
~1200 traits or disorders that are known to portray single gene Mendelian inheritance in 
humans (11), there are an even larger number of disorders which do not follow the 
classical patterns of Mendelian inheritance. In recent years several different mechanisms 
have been recognized accounting for these phenomena, including anticipation, 
mosaicism, uniparental disomy, genomic imprinting and mitocondrial inheritance (13). 
The greatest challenge has been met in the identification of disease genes predisposing to 
complex disorders, also known as multifactorial disorders. Multifactorial diseases are 
caused by multiple genes interacting with each other and environmental factors. They 
display a complex pattern of inheritance, with incomplete penetrance, often delayed age 
of onset and substantial locus heterogeneity. These phenotypically similar diseases do 
not show any Mendelian pattern of inheritance. It is likely that more than one mutation is 
required to produce disease manifestation, and the susceptibility to disease may be 
further mediated by environmental factors in addition to the subtle contribution of a 
number of genes. Complex disorders like diabetes, asthma, cancer and mental illnesses 
are common, especially in western populations. In all of these cases, no one gene has 
been found to manifest the disease. Unraveling the underlying genetic networks as well 
as the effects of their interactions on disease expression will undoubtedly be a challenge 
for some time to come, and will be largely assisted by the ongoing efforts to sequence 
different species as well as the revolutionizing contributions of novel high-throughput 
technology.
2.2 Strategies for mapping genes predisposing to common complex 
disorders
Genetic dissection of even simple Mendelian traits has been sufficiently challenging. In 
recent years, it has become increasingly evident that complex disorders pose a unique 
challenge that requires more imaginative approaches than ever before. Common complex 
disorders can generally be divided into different classes such as psychiatric disorders 
(e.g. bipolar disorder, schizophrenia, unipolar depression), metabolic disorders (e.g. type 
2 diabetes, obesity), and autoimmune and inflammatory disorders (thyroiditis, systemic 
lupus erythematosus, multiple sclerosis, type 1 diabetes, asthma, atopic disorders) (14).  
It appears that genes with large effect size in complex disorders are relatively rare. 
Instead, the genetic make-up seems to be more of an oligogenic (i.e., a few genes each 
with moderate effect size) or even polygenic nature (i.e., many genes, each with small 
effect size), in addition to influencing epigenetic factors. To search for the underlying 
disease variants by examining the genome base-by-base is not yet a reality, thus 
alternative approaches are utilized. The most widely used methods are linkage analysis, 
association analysis, allele-sharing methods and animal models (15). 
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2.2.1 Statistical methods 
The two main statistical approaches are linkage and association studies. While linkage 
studies seek to identify loci that co-segregate with the trait within families, association 
studies seek to identify particular variants that are associated with the phenotype at the 
population level. These are complementary methods that together provide the means to 
probe the genome and describe the genetic etiology of complex human traits, potentially 
elucidating the mechanisms leading to some of the most important contemporary disease 
mechanisms. 
2.2.1.1 Linkage analysis 
Parametric lod score methods 
The most commonly used statistic is the logaritm of the odds ratio (lod score). This 
statistic assesses the probability of two loci on a chromosome being linked, and therefore 
not being transmitted independently from parent to offspring. Traditionally the distance 
from disease gene to marker is determined by the recombination fraction, theta (θ), that 
ranges from θ = 0 (no distance) to θ = 0.5 (no linkage). In 1955 Morton described this 
statistic in the following formula, which assesses the probability that the co-segregation 
of illness and marker allele has occurred randomly, versus the probability that the co-
segregation of illness and a marker allele has occurred because the marker allele is 
located near a disease gene on the same chromosome, such that the two are transmitted 
together more often than expected by chance (=50%): 
Z (θ) = log 10  [L (θ) / L (0.5)] 
in which L is the likelihood function and θ is the recombination fraction. The overall 
likelihood of a pedigree is determined, for a range of θ values (θ = 0 to θ = 0.5), and the 
ratio of the likelihoods gives the odds of linkage and the logarithm of odds (Z = lod 
score) at every θ. In a set of independent families, the overall probability of linkage is 
the product of likelihoods of possibilities in each individual family, and the lod scores 
can then be added up across families. For complex disorders the Lod score is maximized 
over θ (Zmax ), which is normally the statistic of interest, since the value of θ as a measure 
of distance is very limited due to confounding by imperfect genotype-phenotype 
correlation (16). 
This statistical method has been successfully applied to localize genes for numerous 
Mendelian disorders. It is considered to be a model-based (parametric) method, since the 
values for several variables have to be specified prior to the analysis. These variables 
include mode of inheritance, frequency, and penetrance of the disease allele (i.e., the 
probability of being ill given one carries the allele). 
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Nonparametric methods  
The traditional lod score method is a very powerful approach, especially in monogenic 
disorders where the required parameters are generally known. However, that is seldom 
the case in complex disorders particularly in diseases that might not develop until later in 
life.  This dilemma is most commonly circumvented by utilizing a so called model-free 
(nonparametric) method. Nonparametric linkage analysis does not require specification 
of a genetic model, since all meioses are considered to be independent and equally 
informative for the disease locus. 
One nonparametric method is based on identification of alleles or chromosomal 
segments that are shared by affected individuals, hence termed allele-sharing method. 
This particular method can be used either within nuclear families (sibpair analysis) or 
within extended families or even in whole populations. In sibpair analysis, segments that 
are identical by decent (IBD) and those identical by state (IBS) are distinguished (17). 
Identical by state alleles look the same and may even be the same DNA sequence, but 
they do not derive from a common known ancestor. Identical by descent alleles, on the 
other hand, are copies of the same ancestral allele. The shared segment analysis can be 
conducted using either IBS or IBD data. Affected sibling pair analysis (ASP) is a 
commonly used approach derived from the allele-sharing method that assumes that 
sibling pairs randomly share 50% of their alleles (18). Therefore, if the alleles of a DNA 
marker are located near a disease gene which contributes to the disease in the affected 
siblings, they will tend to share alleles to a greater extent then by chance alone. 
Linkage analysis, parametric or nonparametric, can be conducted either by comparing co-
segregation of one marker and the disease phenotype (two-point linkage analysis), or by 
extracting the information from numerous markers simultaneously (multipoint analysis). 
2.2.1.2 Association analysis 
Linkage analysis is a very robust way to localize a linked genomic region, however even 
at its best its genetic resolution is limited to 1cM (19). This is approximately equivalent 
to 1 000 000 bp of DNA, which means that this region can hold tens of genes. Hence, an 
alternative strategy is needed in order to further narrow down the original linked region. 
For this purpose, association analysis that is based on linkage disequilibrium (LD) is 
utilized. The pattern of LD along a chromosome is shaped by the absence of meiotic 
recombination, thus genomic segments are inherited in blocks from generation to 
generation, sharing a single genealogical history across their length. The LD is 
influenced by evolutionary forces such as drift, migration, admixture, and rapid 
population expansion, thus, it is strongly dependent on population history. Association at 
population level between a marker and the phenotype of interest can be observed under 
either of two circumstances; when the functional variant is studied directly, or when the 
marker variant is in LD with the functional variant.  
Association studies can either be based on case-control samples where frequency of 
alleles of unrelated affected subjects are compared with alleles of unrelated unaffected 
subjects, or on family-based studies. A large case-control study sample can feasibly be 
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obtained, and is also the most stastically powerful in the case of no bias. However, the 
difficulty in matching the controls adequately for age, sex, and ethnicity frequently 
creates stratification bias and leads to false positive association (20). In order to 
circumvent this problem several family based control association methods have been 
developed. Two of the most frequently used methods are haplotype based haplotype 
relative risk (HHRR) method (21), and transmission/disequilibrium test (TDT) (21, 22). 
Both methods use the non-transmitted alleles to the affected subjects from the parents as 
internal controls, thus matching perfectly for ethnicity (21). The main difference between 
the two methods is that the TDT test extracts only the allele data from the heterozygous 
parents, while HHRR method also extracts it from homozygous parents. To date, even 
more efficient new methods have been developed that enables the analysis of linkage and 
LD jointly (e.g. Pseudomarker) (23), which opens the door for testing of a whole new 
range of different types of study samples.  
2.3 Genome-wide approach 
There are two general strategies for identifying complex trait loci depending on what is 
known about the trait biologically. If no reasonable hypothesis-based candidate genes 
can directly be tested, the second strategy, a hypothesis-generating approach is 
considered instead. In this case, anonymous polymorphisms uniformly distributed 
throughout the genome (traditionally about 400 microsatellite markers for linkage 
studies) are tested for presence of linked trait locus at each of the loci. This so called 
genome-wide scan strategy represents a unique tool for detecting previously unknown 
trait loci.  
Conventionally linkage analysis is used to uncover linked loci throughout the genome in 
these types of studies, although now marker sets for genome-wide scans based solely on 
association analysis have been developed. However, for the traditional genome-wide 
scans, large sample sets of families or affected sibling pairs are required. Linkage 
analysis uses DNA sequences with high variability in order to increase the power to 
identify markers that are linked with the disease of interest within families. Earlier 
linkage studies applied restriction fragment length polymorphisms (RFLPs) (24), 
whereas for many years now short tandem repeat polymorphisms (STRP), also known as 
microsatellite markers, have been utilized (25). To date, several sets of microsatellite 
markers have been published (26), resulting in very dense marker maps with 
approximately 1cM intervals. These DNA sequences represent characteristically short 
sequences with 2-4 bp repeats, appearing approximately every 30 kb in the human 
genome. They show considerable variability among people, but most of the time these 
sequences have no functional consequences. More recently a new generation of 
polymorphic markers, single nucleotide polymorphisms (SNPs), have taken over linkage 
and association studies to track diseases in families. SNPs represent a major contribution 
to genetic variation accounting for approximately 80% of all known polymorphisms in 
the human genome. They are relatively evenly spread throughout the human genome (ca. 
one in every ~ 1250 nucleotides) therefore providing markers within the immediate 
vicinity or even at the locus of interest. Leading biotechnology companies have devolped 
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their own platforms for screening thousands of SNPs enabling whole-genome studies 
using a single array chip. For example, Affymetrix has commercially available a 500K 
Array Set, which comprises of two arrays both holding 250 000 SNPs. Competitors such 
as Illumina that already have on the market a chip with over 100 000 SNPs, are also now 
also releasing a 250K chip. The genotyping technology is developing fast and new more 
powerful methods are constantly on the rise. 
The procedure behind a genome-wide screening is rather straightforward, however great 
difficulties have been met in the application and the interpretation of the results. Thus, in 
1995, Lander and Kruglyak performed a simulation analysis of a fully informative 
marker map (27). Based on the conclusions drawn from that study statistical guidelines 
for judging validity of genome-wide scan linkage results in complex disorders were 
suggested that are still widely used. This simulation analysis showed that the traditional 
lod score 3.0 as a threshold for significant linkage needed to be increased to 3.3 in order 
to achieve a true genome-wide significance.  In other words, with this threshold 
statistical evidence of this magnitude would be expected to occur 0.05 times in genome-
wide scan by chance alone. It was further recommended that a lod score of 1.9 should be 
considered as suggestive evidence for linkage, since values of this level are expected to 
occur randomly about once per genome scan. For study designs based on ASP, the 
corresponding scores (MLS) are 3.6 and 2.2, respectively (Table 1). Overall, the general 
conclusion is that until an original significant linkage finding has been confirmed (lod 
score ≥ 1.2 or P ≤ 0.01) in an independent study sample, it will be considered a false 
positive (type I error) (27). 
2.4 Candidate gene approach 
Candidate genes are implicated in the genetic basis of a phenotype either on the basis of 
their location in a genomic region that has been identified by mapping studies (positional 
candidate) or because they fit into a proposed model of the physiology of a phenotype 
(model candidate or hypothesis-driven candidate). In this approach the association of 
potentially disease presiposing genetic variants of the gene of interest can directly be 
tested, providing a very powerful genetic tool. Various study samples can be utilized in 
this approach (e.g., case/control-sets, affected sib-pairs and multiplex families). Genetic 
Table 1 
Significance thresholds for genome-wide linkage. 
Method  Genome-wide 
suggestive linkage 
Genome-wide 
significant linkage 
Lod score P value 1.7 x 10-3 4.9 x 10-5
 Lod score 1.9 3.3 
ASP-MLS P value 1.7 x 10-4 2 x 10-5
 Lod score 2.2 3.6 
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markers within or flanking the gene of interest are selected for analysis, and since SNPs 
are on average spaced one every 1250 nucleotides, they provide a magnificent tool for 
testing of association. At present, haplotype blocks (i.e., genomic blocks separated by 
recombination) provide an efficient tool for testing of LD in candidate genes, since fewer 
SNPs need to be genotyped for the same amount of information, providing a more cost-
effective and less time-consuming approach. The recently launched project known as the 
HapMap project aims to develop a map of human haplotypes, or blocks of DNA that 
may have been conserved in evolutionary history. Together with today’s modern 
technology this provides the possibility of genome-wide association analysis. 
2.5 Advantages of isolated populations in genetic research 
One of the most critical phases in a genetic mapping study is the selection of an 
appropriate study sample. Even though the statistical mapping methods can be very 
robust, ultimately they will only reflect the quality of the data being analyzed. As 
previously mentioned, several interacting genes with various penetrances, in addition to 
environmental factors, are involved in complex diseases. Therefore, it is critical to obtain 
the most homogeneous genetic sample possible. Contrary to animal samples where 
breeding, and therefore the genetic background and influencing environmental factors, 
can be controlled, the paramount option in a human population is the use of genetic 
isolates. These arise from small and young populations that have grown considerably in 
size over a short period of time. These usually evolve as a consequence of one or several 
bottlenecks, after which the population is further genetically shaped by the influences of 
genetic drift and the founder effect (28), as well as a varying degree of inbreeding that 
often takes place in most small, isolated populations. All these factors result in the 
isolated populations becoming genetically more homogeneous and some rare recessive 
disorders becoming enriched, while again other common Mendelian diseases might be 
almost non-existent (29, 30). It is believed that because of the genetic homogeneity there 
would be fewer mutations predisposing to complex disorders compared to more mixed 
populations. Consequently, the extent of LD will also be greater in a young population, 
since less recombination events have taken place. This can potentially serve as an 
advantage in decreasing the number of genetic markers needed to test for linkage. 
The Finnish population is among the most studied isolated populations. In fact, genome-
wide scans using family material internal isolates of Finland have already been 
successful in the identification of predisposing loci in in several complex illnesses like 
type 2 diabetes (31), multiple sclerosis (32), familial combined hyperlipedemia (33), and 
schizophrenia (34). Briefly, archeological findings conclude that Finland has been 
inhabited at least 10,000 years (29, 35), suggesting that the first settlers came to Finland 
when the ice melted after the ice age (36). Genetic studies indicate that the current 
Finnish population is comprised of small immigrant populations from the south over the 
Gulf of Finland who arrived in Finland at the beginning of the first millennium (29, 30, 
37, 38). A competing model, the dual-origins hypothesis, contends that two different 
groups settled Finland, identifying the second group to be eastern Uralic speakers who 
migrated to Finland 4,000 years ago (39). Both models assert that the Finnish population 
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has remained isolated for 2,000 years, especially in some of the more sparsely populated 
regions of the country. The relatively large country became sparsely populated by small 
internal immigrant groups migrating slowly from southwestern parts (early settlement) 
towards the north and east (late settlement) (Figure1). It should be emphasized that the 
Finnish population in the late settlement area in the eastern and northern regions of 
Finland is only 300-400 years, or 15-20 generations, of age. The Saami population 
occupying the northern parts of Finland, Sweden and Norway is unrelated to the current 
Finns, and represents an older and more stable population. Archeological findings reveal 
that the founding population of Finland was very small and did not increase much until 
the 1700s due to wars, diseases, and famine, resulting in several bottlenecks. 
Geographical, linguistic and cultural barriers have further sustained Finland’s isolation 
from eastern and western neighboring countries.  
Figure 1.  
Demonstrates the two settlement waves of Finland. 
Early
Settlement
Late
Settlement
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2.6 Bipolar Disorder 
Bipolar disorder (BPD) has been recognized by mankind since the time of the ancient 
Greeks. However, it was not truly separated as a distinct psychiatric illness until the 20th 
century when the German psychiatrist Emil Kraepelin made a distinction between manic 
depression and dementia praecox (later termed schizophrenia). While the acute phase of 
these distinct illnesses may appear similar due to overlapping symptoms, BPD is 
characterized by a sudden onset and a fluctuating course in which the individual returns 
to a relatively normal state between episodes, especially early in the course of the 
disorder. Schizophrenia, on the other hand, is in general characterized by a long 
progressive decline without any significant return to the premorbid state. 
Unravelling the biological underpinnings of a complex disorder like bipolar disorder is 
further complicated by the complexity and variation of illness manifestation as well as 
the elusive linkage between its cyclic nature and its biological substrate. 
2.6.1 Clinical and pathophysiological aspects of bipolar disorder 
Bipolar disorder, or manic-depressive illness, is one of the most serious and debilitating 
mental illnesses. The unique hallmark of the illness is mania, which is characterized by 
prolonged euphoric or irritable mood, racing thoughts, overactivity with a lack of need 
for sleep, disinhibited speech and sexual activity, an increased optimism to the point of 
impairment of rational judgement ability, and distractibility. The manic phase is clearly 
distinct from the patient’s normal personality traits and can last for weeks to months, 
sometimes even years if untreated. The manic phase of BPD commonly cycles with 
alternative features of severe depression, which symptomatically differs from unipolar 
major depression and usually consists of atypical symtoms such as prominent fatigue, 
hypersomnia, and reverse diurnal mood variability (Table 2). Manic-depressive cycles 
are neither random nor predictable, and as many as 40% of bipolar patients experience a 
mixed state, which is a condition with either the coexistence or rapid alternation of 
symptoms of both depression and mania. Many, if not most, patients show a pattern of 
increasing frequency of cycling over time. The lifetime prevalence of BPD in the general 
population is approximately 1%, being similar in both sexes and all races (1). There is 
also an increased tendency for co-morbidity with alcoholism, attention-
deficit/hyperactivity disorder, compulsive disorder, drug abuse and eating disorders. 
Suicide rates for bipolar disorder are alarmingly high, reaching between 10% and 19 %, 
which is 15 times higher than in the general population (40).  
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Table 2. 
Features of Bipolar Disorder 
Feature Mania Hypomania Depression 
Severity of 
disorder
Severity requires 
hospitalization in most 
cases, because of 
major impairment of 
occupational and 
social functioning 
Does not 
require 
hospitalization; 
unusual 
demeanor and 
uncharacteristic 
behavior 
noticeable by 
others, for at 
least several 
days 
Depressed mood or 
reduced interest or 
pleasure in activities, for 
at least 2 wk; behavior 
and demeanor different 
from usual personality, 
causing noticeable 
impairment in social, 
occupational, and other 
areas of functioning 
Symptoms elevated or irritable 
mood;  
feelings of well-being; 
grandiosity or inflated 
self-esteem; 
increased energy; 
decreased need for 
sleep;
talkativeness;  
racing thoughts;  
overoptimistic ideas; 
distractibility; 
increased sexual 
activity and aggressive 
activity; 
increased motor 
activity or agitation;  
poor judgment and 
impulsive behavior 
Same as mania, 
but in milder 
symptoms 
depressed mood; 
loss of interest; 
reduced self-confidence; 
reduced energy; 
insomnia or hypersomnia; 
decrease or increase in 
appetite; 
fatigue;  
feelings of guilt and 
worthlessness;  
poor concentration;  
ideas or acts of self-harm 
or suicides;  
diminished activity  
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2.6.1.1 Diagnosis 
The diagnosis of BPD is based on an evaluation of signs and symptoms in accordance 
with established diagnostic criteria. The first effort to establish a universal diagnostic 
system for psychiatric illnesses was made by the World Health Organisation (WHO) in 
1948 when they published “International Classification of Diseases” (ICD). Successive 
versions of the ICD, now undergoing its tenth revision (ICD-10), represent the official 
diagnostic symtem used by clinicians throughout most of the world. The major exception 
is the United States, where clinicians use the American Psychiatric Association’s (APA) 
Diagnostic and Statistical Manual (DSM), currently in it’s fourth edition. The APA’s 
first diagnostic manual (DSM-I) was published in 1952 and although developed 
independently from the ICD, they are today generally parallel to each other. 
The diagnosis of bipolar disorder is seldom straightforward, sometimes being confused 
with schizophrenia, and often confounded by comorbid substance abuse. Further, the 
severity of manic episodes varies among patients. Based on the variation in acuity and 
duration of manic symptoms, three distinct groups evolve. In addition to the main groups 
(BPD-I, BPD-II, Cyclothymia), also four subgroups have been distinguished in BPD.  
Bipolar Disorder type I (BPD-I) 
Estimates of bipolar disorder type I, or classic manic-depressive illness, have ranged 
from 0.8-1.6% of the population (41). BPD-I represents the most severe form of mania 
that may display a whole range of the characteristic symptoms, and may include 
psychotic symptoms such as hallucinations and delusions, with grandiose delusions 
being the most common. In order to be diagnosed with BPD-I the manic episode must 
last at least 1 week. 
Bipolar disorder I has the highest rate among early onset patients (<15 years of age) (1) 
and over 90% of the BPD-I experience their first manic episode before the age of 35. 
There is a trend towards increase in severity of BPD with earlier age of onset. It is 
thought that most BPD-I cases are treated since the symptoms are behaviorally manifest 
and observable, and manic behavior is clearly distinguishable from ordinary functioning.  
Bipolar Disorder type II (BPD-II) 
Bipolar disorder type II is characterized by mild manic episodes without psychotic
symptoms, which are accompanied by at least one or more depressive episodes. These 
hypomanic episodes have to last at least 4 days and are defined by persitantly elevated, 
expansive mood, with an irritable underpinning. In general, hypomania is not severe 
enough to cause problems in social activities and work. On the contrary, the increased 
energy, self-confidence and creativity can be experienced as an advantage. It is important 
to notice that this episode is still cleary distinguable from the patient’s general 
personality. 
24
The mean age of onset is a bit higher in BPD-II than BPD-I, and the episodes are 
somewhat shorter, however BPD-II still has a strong tendency to become chronic. It has 
been reported that BPD-II has a higher prevalence (~ 5%) than BPD-I, and has also been 
found to be more common among women than men (42, 43). Nevertheless, the exact 
prevalence is hard to determine since BPD-II does not require hospitalization, therefore 
allowing many cases to go undetected and undiagnosed. 
Cyclothymia 
Cyclothymia is a chronic condition of BPD consisting of short periods of mild 
depression and short periods of hypomania lasting only a few days to a few weeks, again 
separated by short periods of normal mood. Individuals with cyclothymia are never free 
of symptoms for more than two months at a time. The prevalence is reported to be about 
6% with no significant difference in sexes (44, 45).  
Subgroups 
Aside from these main groups of BPD four subgroups are also described, namely rapid 
cycling, ultra rapid cycling, seasonal patterning and post-partum onset. BPD patients 
with rapid cycling experience more frequent mood episodes than generally seen in BPD-
I and BPD-II (4 or more per year). Ultra rapid cyclers often experience 4 or more 
episodes per week, but can cycle as rapidly as 4 or more cycles per day. In seasonal 
patterning the onset of the mood episodes can be predicted by a seasonal pattern, and 
post-partum onset is a mood disturbance that occurs within 4 weeks of childbirth. 
Some BPD patients do not fit in any of these descriptions, but clearly present signs of 
BPD (e.g. overlapping a psychotic disorder, hypomanic episodes with no depressive 
episodes). These are classified as BPD not otherwise specified (NOS), which usually is 
the primary diagnosis of an underlying psychiatric disorder that does not presently meet 
full criteria for any of the classically defined Bipoar Disorders.  
Schizoaffective disorder 
Schizoaffective disorder is a schizophrenia-bipolar boundary disorder. It is widely 
debated if it primarily belongs to the affective or the psychotic spectrum, since it 
displays symptoms from both BPD and schizophrenia. The clinical signs and symptoms 
include all features of schizophrenia (hallucinations, delusions, disorganized speech, 
grossly disorganized or catatonic behavior and negative symptoms), mania and 
depression. The schizophrenic and mood disorder symptoms can appear together as well 
as independently, varying greatly from person to person. 
It is not known how common schizoaffective disorder is, but it is believed to be less 
common than schizophrenia and mood disorders. Women may also be more often 
affected than men. To distinguish between bipolar disorder and schizophrenia can be 
particularly difficult in adolescence, since at that age psychotic features are especially 
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common during manic periods. Accurate diagnosis is easier once the acute psychotic 
episode is under control. However, since schizoaffective disorder is so complicated, 
misdiagnosis is common.  
2.6.2 Pathophysiological aspects of BPD 
When reviewing the literature of pathophysiological findings in BPD, the complexity of 
the underlying biological mechanisms is evident, with findings as diverse and 
contradictory as in genetic studies. Even though the research findings to date provide us 
with some insights relating to behavior, brain state and intracellular events, no definitive 
conclusions can be drawn with regard to the individual etiological roles of these factors 
and even less is known about the underlying inter-connectedness of the complex 
biological systems involved. 
Post-mortem studies are a robust way of glimpsing at the pathophysiological aspect of a 
disorder. However, in BPD it is difficult to distinguish the nascent brain changes from 
the ones that are pharmacologically induced by long-term drug treatments. In addition, 
the BPD patients that die at an advanced age are likely to have petrochemical 
abnormalities secondary to other brain disorders, including Alzheimer's disease. 
Conversely, BPD patients that die at a younger age, often by committing suicide during a 
period of acute stress will induce changes in the brain that are not directly linked to the 
underlying biological mechanisms of BPD.  
The advances in technology have provided us with other tools to measure the anatomy
and function of the human brain and its neurochemical abnormalities. These 
sophisticated neuroimaging techniques have opened whole new possibilities in the 
research of brain disorders. With computed tomography and magnetic resonance 
imaging (MRI), structural images of the brain can be attained. Information about brain 
function has also become accessible through the development of functional MRI and 
positron-emission tomography (PET) technology. Most of the imaging studies in bipolar 
disorder thus far have been small, both due to the cost and the difficulty involved in 
studying patients who are either manic or depressed. Thus, the ability to replicate results 
has been poor. At present, neither neuroimaging nor neurochemical studies can be used 
as biologic tests to predict or confirm the diagnosis of BPD.  
The fact that no consistent alterations in regional brain functions have been found in 
BPD is suggestive that BPD is not directly bound to a specific brain region. Although 
strokes can induce manic behavior, these are more likely syndromic expressions of a 
final behavioral phenotype that coincidentally resembles the manic state of BPD. At this 
point, we do not know which is the cause and which is the effect, but it seems clear that 
any alterations in the function of a complex system like the brain will be manifest 
throughout the whole system. Unlike schizophrenia, the fact that most bipolar patients 
return to a state of relative normality, even in the absence of treatment, is strongly 
suggestive for alterations in a modulatory mechanism. 
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Thus far alterations in signal transduction appear to offer the most explanatory premise 
for the range of symptomatology in bipolar disorder. However, the signal transduction 
alterations typically exhibited by patients with BPD represent endophenotypes rather 
than causative biological mechanisms. Similarly, early studies examining urine and 
spinal fluid for abnormalities in metabolites of the chief monoamine neurotransmitters, 
noradrenalin, serotonin, and dopamine were difficult to replicate and, if replicated, turned 
out to be a result rather than a cause of the hyperactivity typical of mania and the 
hypoactivity and weight loss typical of depression. Difficulty discriminating which 
observed biological phenomena play a role in the etiology of the illness, as opposed to 
representing biological markers or biological effects of the illness, is the primary hurdle 
of research in this area. 
2.6.3 Treatment of bipolar disorder 
In the 1950s the treatment of BPD was revolutionized when lithium was identified to 
have mood-stabilizing effects, and it also served as a potential window into 
understanding the disease related alteration at the cellular level. Unlike other medications 
in psychiatric disorders, lithium is a salt, and consequently, does not have a receptor to 
which it binds in the brain. It is actively transported into the cell through the sodium 
channel, and when a neuron depolarizes, the sodium channel opens and both sodium and 
lithium rush into the cell. The sodium is then actively pumped out, using the sodium-
potassium-ATP pump, but lithium remains in the intracellular compartment. Lithium’s 
effect in BPD appears to rely on the modulation of several second messenger systems, 
including cAMP and phosphoinositol pathways (46). Rather than causing large changes 
in baseline cellular activity, lithium seems to attenuate responsivity to other 
neurotransmitters, including serotonin, dopamine, and gamma-aminobutyric acid 
(GABA) circuits. Its efficacy may possibly be more related to its wide-ranging 
neurobiological effects rather than to a single mechanism. One possibility is that lithium 
exerts its effects by resetting the ionic homeostasis in neurons either directly or through 
its interaction with second messenger systems (47).  
The acute phase of mania in BPD is mostly treated with lithium, valproate, and 
carbamazepine. However, there is a growing consensus that in order to obtain an optimal 
response in most BPD patients, multiple-drug therapy is required. Bipolar depression 
generally responds to tricyclic antidepressants, selective serotonin reuptake inhibitors, 
and monoamine oxidase inhibitors. Nevertheless, the new atypical neuroleptic drugs such 
as clozapine, olanzapine, risperidone, and ziprasidone have been shown to pose fewer 
risks of inducing depression than the classic neuroleptic drugs. However, some negative 
adverse effects of these drugs include weight gain, changes in lipid levels, and 
abnormalities in glucose tolerance. It usually takes three to six weeks before the full 
effect of the pharmaceutical treatment can be seen in BPD patients. 
Complicating the treatment and the clinical course further is the common co-morbidity 
of substance abuse among BPD patients. BPD patients in the depressive phase may use 
alcohol or drugs as self-medication and patients in the manic phase may crave them as 
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part of the characteristic arousal of this phase. However, the extent of substance abuse in 
patients with bipolar disorder varies greatly according to culture, country of residence, 
and socioeconomic class. 
2.7 Genetics of bipolar disorder 
For more than three decades substantial evidence has suggested that the major 
psychiatric illnesses of schizophrenia, bipolar disorder, autism, and alcoholism have a 
strong genetic basis. It has been hoped that identification of these genetic factors might 
provide the means to learn more about the neural or biochemical mechanisms of these 
diseases and thus provide a rational basis for the design of effective therapies. About half 
of the patients diagnosed with BPD have a positive family history of the disorder, and in 
some families, the disease has traveled across several generations. Although both genetic 
and non-genetic factors contribute to these diseases, it is clear from the abundant number 
of family, twin and adoption studies that the etiology of BPD is strongly influenced by 
genetic factors (see 3.2.1). The inheritance of BPD appears to be multifactorial in nature 
rather than the result of simple Mendelian transmission, which makes it more difficult to 
isolate the specific genes or combination of genes that contribute to the manifestation of 
the illness. Another major challenge in the genetic studies of BPD is to identify the 
affected phenotype accurately and reliably. Unlike other common medical illnesses, 
robust biological markers have not yet been identified for BPD, forcing exclusive 
reliance upon categorical diagnoses. Attempts to replicate linkage findings have also 
been hampered by genetic heterogeneity, phenocopies, genotyping errors, and the 
complexities of performing and interpreting statistical analysis (15, 27).  
It is recognized that mental disorders arise from complex gene-gene, gene-environment 
interactions, and that no single gene may be either necessary or sufficient to produce any 
mental disorder phenotype. Hence, it is not surprising that like most genetically complex 
medical disorders, mental illnesses exhibit a great deal of clinically significant 
heterogeneity even within families. 
2.7.1 Heritability of bipolar disorder (Family, twin and adoption 
studies)
A clear heritable component of BPD can already be assumed by observing its clear trend 
to aggregate in families, such that family members of an affected individual are more 
often also affected than in comparison to any random person in the general population. 
To date, this assumption is supported by numerous family, twin and adoption studies that 
argue strong genetic contribution to the etiology of bipolar disorder. It should be 
emphasized, though, that within families afflicted with BPD, the nature of inheritance 
often features a cluster of syndromes, that include in addition to bipolar disorder, 
alcoholism, non-specified psychosis, schizophrenia and unipolar depression. 
While family studies indicate the degree to which diseases aggregate in families, they 
alone cannot assess the proportion of genetic versus environmental factors involved in 
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the etiology of a disorder. For this assessment, unusual relationships such as twins, 
adoptees, or half siblings are required. Twin studies consist of monzygotic twins sharing 
100% of their genetic material, as well as dizygotic twins who share on average only 
50% of their genetic material, both still sharing a relatively common environment. By 
monitoring the co-occurrence of a disorder in MZ and DZ twins, a distinction of the 
genetic and environmental factors involved in the disorder can be made. If there is no 
genetic component present in the disorder, the concordance rates are similar for both 
twin types. Thus, in a monogenetic disorder with 100% penetrance, the MZ twin 
concordance will be 100%, whereas the DZ rate will be equal to that of any other 
siblings. However, for multifactorial disorders, the rate for MZ twins will typically be 
less than 100%, but more than for DZ twins. Adoption studies are the most powerful 
design to test the relative contributions of genetic and environmental factors to etiology 
of a disease, but these are more demanding to conduct.  
Family studies in BPD have shown the approximate lifetime risk for a first-degree 
relative of a bipolar proband to be 5%-10%. Twin studies have shown that MZ twins 
have a 75 times higher risk than the general population of contracting BPD if the other 
twin is affected. Even though fewer adoption studies have been performed, these also 
demonstrate that biological relatives of BPD patients are substantially more likely to 
have the disorder than are adoptive relatives. 
2.7.2 Previous genetic findings in bipolar disorder 
During the past 15 years the vast majority of endeavors to find the genetic loci 
predisposing mental disorders have utilized the linkage analysis strategy. Despite this 
effort, a susceptibility gene has not yet been found. The key strategy has been to employ 
genomic markers and to test for linkage among families with multiple affected members. 
However, the outcome during the early years (48, 49) was mostly disappointing when 
the positive linkage findings were not supported by subsequent independent studies (50). 
Today, it is generally recognized that further advances in unraveling the genetics of BPD 
will require the analysis of hundreds to thousands of affected individuals and their 
families. Linkage analysis together with high throughput DNA sequencing, microarrays 
for whole genome scanning, advances in proteomics, and the development of more 
sophisticated computer programs for analyzing sequence and association data hold 
promise of greatly expediting the search for the genetic basis of most mental illnesses, 
while at the same time providing molecular targets for the development of new and more 
effective therapies.  
The history of genetic studies in BPD might appear as manic depressive as the disorder 
itself. Yet, the cycle of apparent discovery followed by diasappointment due to lack of 
replication is a common outcome among most complex disorders. The three main causes 
for this outcome is locus heterogeneity, inadequate sample sizes and inaccurate 
phenotype definition, which is especially problematic in psychiatric disorders. In 
genetics the word heterogeneity refers to two different phenomena, namely locus and 
allelic heterogeneity. Locus heterogeneity refers to the same or closely similar phenotype 
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having causal links to mutations in different genes at different chromosomal loci. Allelic 
heterogeneity describes a state when different mutations in the same gene cause the same 
phenotypes. Both pose their own set of problems in study designs. In linkage analysis 
allelic heterogeneity does not create problems, since linkage to the same chromosomal 
region will still be detected regardless of the specific variation present. Locus 
heterogeneity, on the other hand, will generally overwhelm linkage analysis because of 
the presence of several different genes with the same phenotypic outcome. In association 
analysis, allelic heterogeneity also raises problems as association tests in general depend 
on cases sharing the same allele. And while locus heterogeneity causes fewer problems 
for association studies, it still reduces the power of the analysis. It has been shown in a 
simulation by Suarez et al. (51) that a locus detected in one sample will unlikely be 
replicated in another sample because different study samples are very likely to contain 
differing proportions of families linked to particular loci unless the second sample is 
much larger. 
Three general strategies are commonly used in order to overcome the problems caused 
by locus heterogeneity. First, ascertaining study samples from genetically isolated 
populations, where the number of different susceptibility genes may be smaller, could 
help to deal with heterogeneity. Another approach is to focus on familial patterns of the 
illness, with the assumption that different patterns could point to different susceptibility 
genes (52-55). And finally, selection of families that are enriched for clinically severe 
phenotypes might provide an advantage, assuming that these families may be more 
homogeneous. All of these approaches have one emphasis in common: a constructive 
ascertainment strategy how families that will be studied are selected and identified. 
Ascertainment is a fundamental principle of epidemiology, as it should be in the genetic 
studies of BPD as well. In schizophrenia genetics researchers are on the verge of major 
breakthroughs, mainly because of the large schizophrenia samples that have been 
collected based on a population-based ascertainment scheme that systematically samples 
all families present in a defined region (56, 57). This has subsequently led to 
identification of strong candidate susceptibility genes (58, 59).  
Sample size is still a problem in linkage and association studies in BPD. To date, no 
genome-wide scan candidate gene study has been based on the kind of sample size 
known to be necessary for detection of the underlying biological mechanisms in BPD. 
However, meta-analyses of worldwide genome-wide scans have recently been employed, 
which have facilitated detection of linkage signals that are weaker in effect but consistent 
across studies (60) (61).  
The lack of specific biological markers in BPD causes a lot of problems in genetic 
studies, since the same underlying biology may not be shared among BPD patients and 
therefore the validity of the diagnosis can never ever be guaranteed. One approach that is 
becoming increasingly popular and that copes with this issue is the use of 
endophenotypes instead of DSM-based diagnosis. Endophenotypes attempt to go beyond 
the usual approaches to clinical subtyping based on symptom picture, age at onset, 
comorbidity, treatment response, etc. To date they have increased substantially our 
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understanding of the clinical picture in schizophrenia (e.g., prepulse inhibition) (62), 
panic disorder (e.g., sensitivity to lactate infusion) (63), and alcoholism (e.g., evoked 
potentials) (64), and are as well thought to be genotypically more homogeneous. 
Anticipation is known to involve expansion of segments of the genome consisting of 
trinucloetide repeats. Thus, it is reasonable that such a mechanism may account for the 
earlier onset and increased severity of bipolar disorder in subsequent generations of 
families through which the disorder is segregating. Several studies have shown that there 
are clinical differences between early and late onset BPD. Early onset of BPD have more 
psychotic symptoms (65), more manic episodes (66), and have higher levels of 
comorbidity with conduct disorders, alcohol abuse, drug addiction and eating disorders 
(67). These patients also respond poorly to lithium (68). Anticipation is the phenomenon 
whereby a disease becomes more severe and/or presents with earlier onset as it is 
transmitted down through generations of a family. The only known mechanism for true 
anticipation is a class of mutations containing repetitive sequences exemplified by the 
pathogenic trinucleotide repeats. Studies of bipolar disorder (BPD) are consistent with 
the presence of anticipation and, by inference suggest that trinucleotide repeats 
contribute to this disorder, although it is possible that these data are the result of 
methodological problems. On the assumption that anticipation in BPD may be real, 
several surveys of the genome of BPD probands for large trinucleotide repeats have been 
conducted, as have studies of many repeat-containing candidate genes. 
Genome-wide scans and the most prominent findings 
Numerous genome-wide scans have already been completed for bipolar disorder (69-
110) and all published genome-wide scans in bipolar disorder are presented in Table 3. 
Despite difficulties with diagnostic differences between sample populations and the lack 
of statistical significance in many individual studies, several promising patterns have 
emerged, suggesting that some true susceptibility loci for bipolar disorder may have been 
identified. The strongest and most replicated evidence of linkage in genome scans to date 
are found on chromosomal regions 4p16-p13 (71, 74, 75, 95, 97, 110), 4q21–35 (69-71, 
77, 82, 83, 85, 97, 100, 109, 111), 6q14-q24 (69, 71, 74, 80, 81, 83, 85, 103, 104, 107), 
8q24 (70, 80, 87, 93, 100, 104), 12q21–q24 (69, 73, 74, 77, 79, 98), 13q12-q14 (70, 73, 
87, 89, 93), 16p13–p12 (69, 73, 74, 77, 83, 88, 94) and 18q21–q23 (70, 73, 97, 101, 102). 
However, methodological issues and non-replications again demonstrate that these 
findings are not conclusive. Furthermore, no predisposing genetic variant for BPD has 
yet been found, and like in most complex disorders the linkage peaks are very broad and 
may contain hundreds or even thousands of genes. 
The following chromosomal regions have been implicated in several studies and meet 
the statistical guidelines for confirmed linkage. Hence, these regions are considered 
promising candidate regions in BPD. 
Chromosome 4p16-p13: Blackwood et al. obtained a two-point lod score of 4.1 
(three-point lod score of 4.8 with the neighboring markers) in their genome-wide scan in 
31
one large Scottish pedigree (110). In an effort to replicate the result in 11 smaller 
pedigrees the old score went down to 2.9, with an alpha-value (α) of 0.35 at theta 0.0 (θ). 
Lod scores of similar magnitude were reported by Ginns and colleagues in a mental 
health wellness study of relatives that are at high risk for BPD. In this study they found 
significant evidence of linkage to the 4p15 chromosomal region, the two-point analysis 
providing P-values less than 3 x 10-5 and the NPL multipoint analysis lod scores of 4.1. 
Additional support for this locus comes from three independent genome-wide scans (75). 
First, Ewald et al. obtained a two-point lod score of 2.0, producing an empirical P-value 
of 0.0006 at the same locus in a study of two Danish families (112). Also Detera-
Wadleigh et al. detected a parametric lod score of 3.2 in one of the families, however 
when analyzing their total set of 22 families the signal was slightly weaker (P = 0.0022) 
(95). In the second stage of the Wellcome Trust UK-Irish genome-wide scan Lambert et 
al. found suggestive evidence of linkage (Zmax = 2.2) on chromosome 4p14-p13 (71). 
Chromosome 4q21-q35: Numerous linkage findings have been reported at 
chromosome 4q, however the linkage signals are widely scattered reaching from 4q21 to 
4q35. In 1999 Adams and colleagues were the first to report significant evidence of 
linkage to the more telomeric region (4q35: Zmax = 3.6) (109). Also the recent 
Wellcome Trust UK-Irish genome-wide scan reached statistically significant lod scores 
(Zmax = 3.3), however the linkage peak being located far more centromeric on 4q12-q21 
(71). The same chromosomal region 4q21 was also implicated in a SNP genome-wide 
scan by Middleton et al. screening Portuguese bipolar families (83). They found 
nonparametric lod scores approaching significance reaching 3.0 using a marker map with 
a median intermarker distance of 210kb (83). In the NIMH Genetics Initiative replication 
study Willour et al. found supporting evidence of linkage to 4q35 reaching a lod score of 
2.5. In the same study Willour et al. also reported strong linkage signals merging from 
another region located approximately 40cM more centromeric, on 4q32 (Zmax = 2.2) 
(85). In a subsequent genome-wide scan from Finland, a two-point lod score of 2.5 and a 
significant three-point lod score of 3.6 was obtained with the same exact marker as in the 
NIMH study (77). Interestingly, Ginns et al. reported in their genome-wide scan of a set 
of Old Order Amish bipolar pedigrees a locus in the near vicinity at 4q31 linked to 
mental health wellness (75). The same chromosomal region was implicated in three 
additional bipolar genome-wide scans. First, in a study by Liu et al., where the lod scores 
approached significance (Zmax = 3.2) (75), and then by Friddle et al. that found 
multipoint lod scores of 2.1 in a set of 50 multiplex families (100). Finally, McInnis and 
colleagues published a genome-wide scan with highly dense microsattelite marker map 
of 842 markers and found a nonparametric lod score of 2.8 (Zmax = 1.9) on 4q32 and 2.4 
on 4q35 (Zmax = 1.2) (70).  
Chromosome 6q16-q24: In the third NIMH GI wave 250 bipolar families from the 
U.S were analyzed, one of the regions that yielded significant linkage was on 6q16 
(Zmax = 3.6) (80). Also in a genome-wide scan of 16 extended Portuguese families 
provided close to significant lod scores resulting in 3.1 (81). However, in another study 
analyzing an additional 9 Portuguese families highly significant lod scores were 
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observed. In the preliminary analysis a parametric two-point lod score of 3.6 and a 
nonparametric lod score of 4.2 were found. When further mapping the critical linkage 
region with SNPs a nonparametric two-point lod score of 4.4 was observed (Zmax = 2.6) 
(83). In a Swedish bipolar genome-wide scan 9 multigenerational families provided a 
multipoint lod score of 2.5. However, when further genotyping additional markers in the 
region a multipoint lod score of 3.3 was achieved (107). Additional support for this 
region was also provided from the second stage of the Wellcome Trust UK/Irish 
genome-wide scan (Zmax = 2.6) (71), as well as from a bipolar genome-wide scan of two 
Danish extended pedigrees (Zmax = 2.2) (74). McInnis et al. also published a genome-
wide scan of 153 U.S. families that obtained a nonparametric lod score of 2.8 using a 
conditional analysis method (69). Due to the overwhelming linkage support for this 
chromosomal region an effort between 10 different was made to combine all linkage data 
for this chromosomal region. This particular chromosomal region, 6q22-q24 has been 
identified as a region with numerous imprinted genes (113), thus slightly different 
analyzing strategies were applied. By testing the parent-of-origin effect it showed that 
the affected siblings share the maternal chromosome more often than the paternal (P = 
0.006). In this study lod scores ranging from 2.3 to 5.4 were obtained for 6q when 
analyzed for each locus conditioned on evidence of linkage to the other. Overall the 
potential BPD locus was found to confer a 1.4-fold increased risk (103). Finally, 
McQueen and collogues published a combined analysis of eleven pre-excising genome-
wide scans from different populations (69-71, 78, 80-82, 85, 86, 88, 90, 92-94, 97, 102) 
and found a highly significant lod score of 4.2 on 6q21 further supporting the potential 
involvement of this chromosomal region in BPD (104).
Chromosome 8q24: In a genome-wide scan of 75 bipolar families originating from 
Germany, Israel or Italy significant a lod score was observed on 8q24 (Zmax = 3.6) (93). 
This was replicated by McInnis et al. in 65 U.S. bipolar families yielding a 
nonparametric lod score of 3.1 (Zmax = 2.1) (70). Suggestive lod scores were provided 
by three additional genome-wide scans: the third NIMH GI scan of 250 bipolar families 
(Zmax = 2.5) (80), Friddle et al. with 50 bipolar families from the U.S. (Zmax = 2.4) 
(100) and 13 Australian bipolar families (Zmax = 2.1) (87). The q-arm of chromosome 8 
has remained one of the few regions that remained relatively narrow of the repeatedly 
replicated chromosomal regions in the bipolar genome-wide scans. In addition, in the 
combined genome-wide by McQueen et al. a significant lod score of 3.4 was found 
(104).
Chromosome 12q21-q24: In 1994, Craddock et al. reported familial aggregation 
of affective disorder and Darier's disease on 12q23-q24.1 (114). Subsequently, the gene 
for Darier's disease was identified as a sarcoplasmic/endoplasmic reticulum calcium-
pumping ATPase, ATP2A2 (114). Mutational analysis of this gene identified 17 novel 
mutations that showed some minimal evidence for clustering in the 3' end of the gene in 
Darier's disease patients with neuropsychiatric phenotypes. Further evidence for linkage 
to 12q has been obtained in two large families from the Saguenay Lac St-Jean region of 
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Quebec, a settlement derived from the migration of a small number of founding families 
into this region in the 1830s. In this sample a nonparametric lod score of 3.9 on 12q21 
and even though significant evidence of linkage was not found in the parametric two-
point analysis, lod scores exceeding the threshold for replication were found for several 
markers (Zmax = 1.61) (98). A more recent genome-wide scan from the same group 
provided a parametric lod score of 3.4 and a nonparametric lod score of 5.1 when 
analyzing 18 additional families from the same region (79). In 1998 Barden et al. 
obtained significant evidence of linkage (Zmax = 4.9) in an extended family from 
Quebec. Unfortunately, reconstruction of haplotypes from these data did not identify a 
common haplotype, making it difficult to further define the critical region (115). In 
addition two large Danish families with multiple affected members in several 
generations were genotyped and a two-point lod score of 3.4 (P = 0.00002) was obtained 
approximately 14 cM from the ATP2A2 gene. Haplotypes were successfully constructed 
in each family, and a minimal overlapping region of 3.8 cM was observed in all but one 
bipolar patient (116). Several other genome-wide scans from different populations have 
all provided lod scores exceeding 2.0 (70, 73, 77). 
Chromosome 13q12-q14: Two separate genome-wide scans have published significant 
linkage results on the same chromosomal region on 13q. Cichon et al. screened 75 
German families for bipolar disorder and found a nonparametric multipoint lod score of 
3.4, nonparametric two-point lod score of 3.3 and parametric lod score of 2.3 on 13q12. 
In 2001 Badenhop obtained a significant nonparametric multipoint lod score of 4.1 (NPL 
Zmax = 2.9, Zmax = 3.0) in a multiplex Australian family. By constructing haplotypes 
they restricted the critical linked genomic region to 6cM that included genes like the 
serotonin 2A receptor (89). When conducting another genome-wide scan with 13 
additional families the same region still showed evidence of linkage (Zmax = 2.3) (87). 
Additional support for these findings have been obtained in two other genome-wide 
scans. McInnis et al. found a nonparametric lod score of 2.4 when screening 65 U.S. 
bipolar families (70). Maziade and colleagues combined a bipolar and schizophrenia 
family sample and found as a result a lod score of 2.7 on 13q14 (73). This region has 
been implicated in several schizophrenia linkage studies as well, suggesting a potential 
shared predisposition for both disorders. 
Chromosome 16p13-p12: Significant linkage has been found in three recent 
genome-wide scans all screening bipolar families from different populations. Ekholm et 
al. reported a significant two-point lod score (Zmax = 3.4) in a Finnish bipolar study 
sample on 16p12 (77), which was shortly replicated by McInnis and colleagues 
performing a conditional analysis on 153 U.S. families (NPL Zmax = 3.3, Zmax = 2.5) 
(69). The most significant lod score was found in the bipolar and schizophrenia 
combined genome-wide scan by Maziade et al.. They found a maximum lod score of 4.1 
when only analyzing the bipolar families, however when combining the entire sample 
the lod score dropped to 3.7. Nonetheless, this still remains a highly significant lod score, 
but is indicating that the lod scores are being driven by the strong linkage in the bipolar 
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families (73). The earlier linkage findings found by Edenberg in the first wave of the 
NIMH GI in 1997, they obtained a suggestive lod score of 2.5 (94). This was replicated 
by Dick et al. in a follow-up replication study (Wave 2 of the NIMH GI) with 56 new 
bipolar families yielding a maximum lod score of 2.8 (88). In genome-wide scan of two 
multiplex Danish families Ewald and colleagues found a two-point parametric lod score 
of 2.2 (74). Same region was again implicated in a genome-wide scan in Portuguese 
families (Zmax = 2.9) that covered the genome with a dense marker map of 11 560 SNPs 
(83). 
Chromosome 18q21-q23: In addition to the signal on 18p, Stine et al. noted 
excess allele sharing at 18q21 (P = 0.0004), approximately 40 cM from the region on 
18p implicated in the original report by Berrettini et al. (117). This finding was 
supported in a genome scan of two large Costa Rican families, where several markers 
that mapped to 18q22-23 yielded lod scores that were marginally positive (Zmax = 1.0
2.3) in each family individually as well as when combined. In addition, haplotypes were 
reconstructed and a large region (~ 40 cM) displayed excess allele sharing. The evidence 
for linkage and association was evaluated jointly in a test estimating the recombination 
frequency and proportion of disease chromosomes sharing a common allele to derive a 
linkage/association-based lod score of 3.7 and 4.1 for the best markers, respectively 
(118). Significant lod scores were also reported by a recent combined bipolar and 
schizophrenia genome-wide scan by Maziade et al.. When analyzing all the families with 
both BPD and SZ they found a significant parametric two-point lod score of 4.5, 
however this signal was not seen when only analyzing the bipolar pedigrees (73). Fallin 
et al. screened 41 Ashkenazi Jewish families and found a suggestive nonparametric 
multipoint lod score of 2.2 on 18q22 (102). The same chromosomal region was 
implicated by McInnis et al. when studying 65 U.S. families (NPL Zmax = 2.9) (70). 
Following these initially encouraging reports, several other groups investigated families 
for chromosome 18 markers. A Jewish Ashkenazi family and a Belgian family were 
genotyped for 14 markers, and several markers in the region of 18q21.33-q23 showed 
excess allele sharing (Pmin = 0.0007) as well as a multipoint lod score of 1.34 for these 
markers. It is interesting to note that a small parent-of-origin effect was again detected, 
but it was not consistently paternal (102). Finally, Nothen et al. reported nonparametric 
lod scores of 2.0 in the region of 18q22-23 (119).
The litterature is relatively sparse on how to interpret several positive findings in the face 
of an equal or larger number of negative findings for the same markers. Furthermore, if 
impressive P values are obtained for different diagnostic models, these cannot be 
considered as simple replications. A single replication study meeting the P = 0.01 
criterion in the face of multiple negative studies must therefore be interpreted with 
caution, unless it can be clearly demonstrated that the negative studies were 
underpowered and thus unable to detect the effect. The absence of findings in the 
overwhelming majority of genome scans suggests that the initial observation may have 
been a false positive. Of course, it is impossible to rule out a gene that confers a very low 
risk of bipolar disorder.
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Table 3. 
Genome-wide scans conducted in bipolar disorder 
Study
(first author, year) 
Sample Pedigrees 
 (n) 
Affecteds 
 (n) 
Number of 
markers (n) 
     
Coon (1993) Utah 8 51 328 
Straub (1994) U.S./Israeli 47  5-153/family 
McInnes (1996) Costa Rica 2 24 473 
Blackwood (1996) Brittish 12   
Polymeropoulos (1996)     
NIMH GI Wave 1 U.S. 97 320 319 
Detera-Wadleigh (1997) (Indiana University,   127 
(chr.4,7,9,18,19,20,21) John Hopkins University,     
Edenberg (1997) Washington University,   74 
(chr. 3,5,15,16,17,22) NIMH)    
Rice (1997)    65 
(chr. 1,6,8,10,12)     
Stine (1997)    53 
(chr. 2,11,13,14,X)     
Admas (1998) Australian 11 58 214 
Ginns (1998) U.S. Old Order Amish 4 50 980 
Detera-Wadleigh (1999)  U.S: NIMH/Amish 22 276 607 
Morissette (1999) Quebec 2 86 332 
Friddle (2000) U.S: Hopkins 50 236 267 
Foroud (2000) U.S. 97 414 365 
Murphy (2000) Irish 45 130 65 
Cichon (2001) German/Israeli/Italian 75 275 382 
Badenhop (2001) Australian 1 6 400 
Kelsoe (2001) U.S/Canada 20 76 443 
Maziade (2001) Eastern Quebec 21 254 220 
Turecki (2001) Canadian 31 106 378 
Radhakrishna (2001) Turkish 1 34 230 
NIMH GI Wave2 U.S. 56 228 296 
Dick (2002) (Indiana University,   84 
(chr. 3,5,15,16,17,22) John Hopkins University,     
Zandi (2003) Washington University,   105 
(chr. 2,11,13,14,X) NIMH)    
Willour (2003)    107 
(chr. 4,7,9,18,19,20,21)     
Ewald (2002) Danish 2  613 
Badenhop (2002) Australian 13 69 400 
Bennett (2002) Irish/British 151 367 398 
McInnis (2003) U.S. 153 641 513 
Curtis (2003) British/Icelandic 7 68 365 
NIMH GI Wave3 U.S (10 sites*)    
Dick (2003)  250 1964 391 
Ekholm (2003) Finnish 41 137 389 
Liu (2003) U.S 40 307 343 
McInnis (2003) U.S. 65 302 842 
Fallin (2004) Ashkenazi Jewish 41 97 382 
Macgregor (2004) Scottish 13 132 372 
Pato (2004) Portuguese 16 47 366 
Faraone (2004) U.S. :NIMH Wave2 97 415 319 
Middleton (2004) Portuguese 25 140 11 560 SNPs 
Lambert (2005) Irish/British 232 622 198 
Maziade (2005) Quebec 21 129 607 
Ewald (2005) Cuban 22  1 494 SNPs 
Shink (2005) Quebec 20 218 380 
Venken (2005) Swedish 9 46 380 
McQueen (2005) Combined analysis of 11 
pre-existing genome-wide 
scns
1 067 2 423 4 510 
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Candiate gene studies in bipolar disorder 
The selection of susceptibility candidate genes for BPD has been based on two different 
strategies, regional candidate genes within linked regions and genes that potentially could 
be functionally involved in BPD. The sequencing of the human genome and identification 
of numerous SNPs should substantially enhance the ability of investigators to identify 
disease-causing genes in these areas of the genome. General observations can be made 
about the difficulties in identifying disease genes for schizophrenia and bipolar disorder. It 
appears that studies of schizophrenia have produced more convincing evidence for linkage 
than those for bipolar disorder for several reasons including the use of larger sample sizes, 
a narrow phenotype, and more conservative and uniform data analysis.  
Mapping a locus by linkage methods to a narrow region requires even more families. As 
a result, both positional and model candidate genes for psychiatric disease are identified 
with less confidence than for Mendelian disorders. Penetrance – the likelihood that a 
person carrying a mutation will develop the characteristics caused by that mutation – is 
likely to be low for most susceptibility alleles in psychiatry. This is because it is believed 
that many such alleles must occur in the same individual for the expression of complex 
psychiatric phenomena and because environmental factors probably have a large role in 
the expression of psychiatric disease. As a result, the concordance of susceptibility 
variants with disease will be incomplete. Association analysis in which variant allele 
frequencies are compared in cases and controls can be used to demonstrate partial 
association of specific variants with disease, but these will be of only moderate 
magnitude and require further validation. It is the reliance on statistical evidence of 
allelic association that most distinguishes the genetic study of complex traits from 
Mendelian traits in the post-genomic era. There are no accepted biological markers of 
psychiatric disease, and those markers that have been proposed, such as levels of 
hormone and neurotransmitter metabolites in serum, cerebrospinal fluid or platelets, are 
themselves likely to result from complex interactions between multiple gene products 
and epigenic factors. Most candidate genes that have been studied in psychiatry are 
involved in neurotransmission of the biogenic amines: 5 hydroxytryptamine (5-HT; 
serotonin), dopamine and noradrenaline (norepinephrine). These genes have been studied 
as the result of the neurotransmitter hypothesis of psychiatric disease, which has been 
dominant since the 1950s. This model of psychopathology was developed when the first 
successful antidepressant and antipsychotic medications were discovered and found to 
modulate the metabolism of biogenic amine neurotransmitters. As genes for components 
of biogenic amine neurotransmission systems were cloned and variants were identified, 
they were used as candidates in genetic association studies of various psychiatric 
disorders. These genes comprise only a small fraction of the possible candidates for 
psychiatric disease, and the evidence supporting their roles in psychiatric disease is not 
strong, particularly when compared with model candidate genes for Mendelian disorders. 
Thus, these genes are unlikely to represent the major determinants of psychiatric 
phenomena. It is possible that these genes have a role in defining mood, perception and 
behavior, but variants in any single one of these genes probably have only a small effect. 
The main weak point of the genetic approach to complex phenomena is that any single 
variant might have only small effects on clinically observable phenomena. The 
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relationship between genotype and phenotype is very stable and reliable but is also likely 
to be relatively weak. This is particularly important to appreciate for model candidate 
gene studies because the intent of these studies is to test a specific hypothesis that is built 
on data from studies of biological markers of CNS function. The very nature of complex 
psychiatric diseases ensures that there will be few major disease genes. That is, even 
very well designed and executed studies will identify susceptibility variants that only 
partially explain the risk for the disorder in individuals who possess these variants. To 
have convincing explanatory power, candidate gene studies in psychiatry must be very 
powerful statistically and supported by functional studies that (1) define a 
neurobiological role for the candidate gene, and (2) demonstrate an effect of associated 
variants on the function of the candidate gene product. There are three factors that reduce 
the impact of specific variants in association studies of psychiatric disease. The first is 
that these complex phenotypes result from the coordinated effects of variants in several 
genes. Besides this basic limitation of association analyses of candidate genes in 
complex phenotypes are the additional concerns of allelic and nonallelic heterogeneity. 
Allelic heterogeneity refers to different variants in the same gene that contribute to a 
phenotype. Allelic heterogeneity is seen commonly in Mendelian phenomena such as 
cystic fibrosis, familial breast cancer and familial Parkinson disease. In these occations, 
genotyping for specific mutations in different families would show no evidence of 
association. The final factor that reduces the effect of specific variants on psychiatric 
disease is nonallelic heterogeneity. This essentially results from phenocopies or closely 
related phenotypes of distinct genetic basis that are not differentiated clinically. Again 
there are examples of this in Mendelian genetics, as the several different genes that cause 
familial forms of deafness, Parkinson disease and retinitis pigmentosa. In psychiatry, this 
problem is likely to be exacerbated because diagnosis relies heavily on clinical 
asessment, which makes subtyping of psychiatric disease difficult and unreliable. In 
addition, pathogenomic markers do not currently exist in psychiatry. By contrast, for 
neurological disorders such markers can help distinguish subtypes of the condition for 
genetic analyses; for example, Lewy bodies in Parkinson disease. Allelic and nonallelic 
heterogeneity dilute the association of specific variants with disease, even when those 
variants are meaningfully related to the pathophysiology of disease. As a result, 
association studies of psychiatric phenotypes must be designed to be very powerful 
statistically. Few studies attempt to sample all of the common genetic variation in the 
gene of interest, and many use older, relatively uninformative markers. Some studies 
focus appropriately on genetic variation that has potential consequences on gene 
function, but the evidence for actual functional effects of that variation in vivo may not 
be clear. Several studies attempt to increase power by splitting the sample into clinically 
defined subgroups, but this requires statistical correction for multiple testing and it is not 
always clear how best to do this. Since association studies are relatively easy to carry 
out, many negative studies are probably never published (120). Because of these 
limitations, the vast majority of potentially important candidate gene markers have yet to 
be confidently excluded from a role in BPD. The larger problem with candidate gene 
association studies is that good candidate genes for BPD are hard to define. We do not 
yet know enough about the biochemical pathways underlying BPD symptoms - much 
less the large groups of genes and even larger number of genetic variants involved - to 
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make a truly educated guess in selecting candidate genes for study. Unless the prior 
probability is reasonably high (better than 1 in 1,000) that a particular gene 
polymorphism is in fact causally related to the disease, Bayes' theorem shows that most 
statistically significant association findings at the P = 0.001 level will actually be false 
positives. If we assume that there are about 30,000-60,000 human genes and that any 
could be a candidate for BPD, then the prior probability that a particular gene is a disease 
gene is no better than one in 30,000. If we only consider those genes expressed in the 
central nervous system (CNS), the denominator might be cut in half, but the odds are still 
very low. We cannot even confidently exclude the possibility that disease-relevant 
variants do not lie within genes at all, but rather in intergenic regions, the functional 
importance of which we still are far from comprehending fully. Association studies in 
regions of genetic linkage face more favorable odds from the start. The prior probability 
that a gene in a linkage region is causally involved in disease is not hard to estimate: it is 
approximately equal to the probability that the region is truly linked, divided by the 
number of genes in the region.  
Animal models for bipolar disorder 
The recent development of microarray technologies has made the simultaneous 
measurement of mRNA levels for thousands of genes possible, hence enabling gene 
expression profiling. The application of this approach to animal models provides a 
powerful tool for the discovery of novel genes involved in disorders, as many molecular 
genetics and histochemical experiments are not feasible in humans. Recent advances 
regarding the underlying neural mechanisms, etiology, genetics, and new 
pharmacological approaches have facilitated the development of new animal models of 
psychiatric disorders. The potential utility of animal models in psychiatry is quite 
substantial because preclinical evaluation of diverse psychotropic drugs relies on the 
utilization of animal tests to produce information concerning the biochemical effects of 
these drugs on specific targets. Nonetheless, the usefulness and acceptance of animal 
models in psychiatry vary widely due to obvious limitations in trying to mimic aspects of 
higher cognitive human functioning in other animal species. Bipolar disorder has turned 
out to be particularly challenging when trying to develop an adequate animal model. The 
alternation of mania, depression, euthymia, and mixed states that these patients often 
present will be extremely challenging to mimic in one and the same animal model. It is 
also important to remember that BPD is influenced by a variety factors, ranging from 
biological to genetic, as well as environmental. Today, several animal models have been 
proposed to reflect behavior of either one of the core features, depression or mania, 
however no models incorporate both components in alternating fashion and therefore fail 
to mimic the hallmark of BPD. 
The value of animal models of BPD is evident, besides providing understanding of the 
pathophysiology of the illness, they also aid in developing newer pharmacologic agents for 
treatment. It includes models that reconstruct the etiology and pathophysiology of BPD.  
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3. Objectives of the study 
The main aim of the current study was to elucidate the unknown genetic component of 
bipolar disorder. Since no predisposing gene has yet been found for this severe mental 
disorder, the general strategy was to localize susceptibility loci in our family sample set 
using a variaty of statistical analyzing strategies. 
The specific aims of this study were: 
1. To further investigate the previous significant linkage finding to Xq24-
q27 in one family from an isolated region in Finland, and narrowing 
down the critical linked region. Our aim was also to validate the finding 
in a nationwide family sample. 
2. To scan the genome for possible linked region to bipolar disorder in our 
nationwide family sample. 
3. The aim was to confirm previous linkage findings as well as detecting 
new ones by re-analyzing the results from 18 different bipolar genome-
wide scans using a meta-analysis strategy. By obtaining alluded results 
their general significance could be emphesized since they would hold 
true across several different populations.  
4. To utilize different statistical strategies to extract linkage information for 
related psychiatric traits in order to increase the statistical power to 
detect linkage.  
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4. Material and methods 
Please refer to the original publications (I-IV) and references for more detailed 
description of the studies. 
4.1 Study samples  
4.1.1 The ascertainment of the bipolar family sample 
The bipolar study sample was collected through utilization of several nationwide 
registers. First, all individuals that were born between the years 1940-1969 and 
hospitalized for ICD-defined BPD, were identified through the National Hospital 
Discharge Register. This register indexes all admission and discharge dates and primary 
diagnoses for inpatient stays at public and private hospitals. In order to link these 
individuals to their first-degree relatives the National Population Register containing 
information on place of birth, residence, marital status and first-degree relatives for each 
Finnish citizen was used. With the aim of ascertaining a study sample for BPD that 
would be more genetically loaded, some further criterias were required from the 
probands; the age of onset had to be before the age of 30 and the patient had to have two 
or more admissions due to BPD, and in addition the probans had to have at least one 
sibling. Also, at least one of the parents had to be born in the Eastern part of Finland 
(Kuopio and North-Karelia) were BPD seemed to be enriched. Next, an extensive search 
was made for all available records from hospitals, clinics, general practitioners, reports 
from medico-legal experts and various other sources that might provide diagnostic 
information. Two psychiatrists, being unaware of the family relationships, made 
independent diagnoses of the subjects based on all available case notes according to 
DSM-IV diagnostic criteria for bipolar I disorder. In addition, the BPD study sample 
includes six families from a Finnish population based study on schizophrenia. In these 
families there were at least one member suffering either from bipolar disorder or 
schizoaffective disorder, bipolar type. Finally five hierarchical diagnostic categories 
were assigned to the study sample; (I) bipolar disorder type I; (II) schizoaffective 
disorder, bipolar type; (III) bipolar disorder type II, bipolar NOS, cyclothymia; (IV) 
recurrent major depressive disorder; (V) other mental disorders. 
The permit for the register searches was obtained by the ethical committee of the 
National Public Health Institute, and the requests to participate in the study were sent to 
the probands fulfilling BPD diagnostic criteria through their treating psychiatrist. If 
permission was obtained from the proband, the family members were contacted. 
4.1.2 Family P101 
One extended BPD family, pedigree P101 was ascertained by Dr. Bredbacka. All family 
members were interviewed by a psychiatrist using SADS-L (121), on at least two 
occations. The diagnoses were made independently and blind to the family relationships 
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Bipolar disorder I
Recurrant major depression
Schizophrenia, alcoholism, neurotic disorders, 
psychosis NOS  
on the basis of interviews and case notes in accordance with RDC (121) and the DSM-
III-R (American Psychaitric Association 1987) by two psychiatrists. The family P101 
consisted of 64 individuals, representing bipolar disorder in four generations (Table 4). 
Figure 2. 
Presents the familytree of pedigree P101. 
Table 4.  
Diagnostic description of family P101 
Number of 
affected
Individuals 
StatusI StatusII StatusIII Status IV Status V 
Family P101 8 0 0 3 6 
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4.1.3 Nationwide family sample 
The nationwide study sample consisted of 40 families in addition to family P101. Three 
of these 40 pedigrees represented extended pedigrees, while the remainder was nuclear 
families. In its entirety the family sample of the 41 families consisted of 341 individuals 
of whom 137 were coded as affected (Table 5). Altogether the sample consisted of 81 
males and 73 females, with an average age of 55.14 years. 
4.1.4 Meta-analysis sample 
In the worldwide BPD meta-analysis altogether 18 genome-wide scan samples were 
analyzed jointly. Several different diagnostic clusterings had been used in each study, 
hence a new diagnostic categorization was applied in the meta-analysis. Two primary 
narrow models were chosen, the very narrow one coding BPD-I and SZ-AFF cases as 
affected (347 pedigrees and 948 affected), and the narrow one including BPD-I, SZ-AFF 
and BPD-II cases as affected (512 pedigrees and 1733 affected) (Table 6). However, 
since recurrent major depression is the most common disorder in BPD families, 
secondary analysis on broader diagnostic classification was also conducted. The broad 
model included BPD-I, SZ-AFF, BPD-II and recurrent major depression as affected (593 
pedigrees and 2437 affected), and the very broad model included in addition also single 
episode major depression and cyclothymic disorder (617 pedigrees and 2589 affected).  
Table 5.  
Diagnostic description of the nationwide family sample 
Number of affected individuals Affection 
status I 
Affection  
status II 
Status I & II 
40 families 93 27 120 
Only family P101 8 9 17 
Total sample 101 36 137 
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*  Fam : Number of families 
**  Aff: Number of affected subjects 
***  M1: Model 1 (BPD-I and SZ-AFF) 
****  M2: Model 2 (BPD-I, SZ-AFF and BPD-II) 
Table 6. 
Descripton of the family samples analyzed in the meta-analysis. 
STUDY 
SITE
FIRST AUTHOR Fam 
*
Aff 
**
M1 
***
M2 
****
BPD-I SZ-
AFF
BPD
-II
Very 
narrow 
analysis:
        
NIMH Detera-Wadleigh 97 424 264 336 232 32 72 
U.K/Irish Bennett 151 367 288 325 288 12 25 
Columbia Liu 39 297 115 208 101 14 93 
Finland Ekholm 41 132 107 107 95 12 2 
Sydney 1 Badenhop 13 69 40 44 33 7 4 
Sydney 2 Schofield 15 63 41 46 31 10 5 
Quebec Morissette 5 56 42 42 39 3 5 
Edinburgh Blackwood 7 41 27 36 27 8 1 
Costa 
Rica
McInnis 2 24 24 24 22 2  
Total    948 868 80 
Narrow 
analysis:
        
Hopkins/
Dana
McInnis 65 301  232 129 6 97 
Bonn Cichon 75 245  128 104  24 
NIMH-IM Detera-Wadleigh 22 160  118 64 18 36 
USCD Kelsoe 20 76  48 33  15 
UC
London 
Curtis 7 74  39 24  15 
Total     1733 1222 124 394 
Broad 
analysis:
        
Ottawa Turecki 31 106   33 3 25 
Antwerp 1 Van Broeckhoven 10 56   14 1 15 
Utah Coon 8 51   20  12 
Antwerp 2 Van Broeckhoven 9 47   22 2 6 
Total      1311 130 452 
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4.1.5 Combined analysis sample 
In the combined analysis two Finnish genome-wide scan study samples were pooled, one 
bipolar study sample and one schizophrenia study sample. The bipolar family study 
sample that was already earlier described consisted of 41 families and 137 affected 
individuals. The larger schizophrenia genome-wide scan study sample was ascertained 
using the same collection strategy, consisted of 238 schizophrenia families and 591 
affected individuals. The aim of this study was to test shared phenotypic entities of both 
disorders in order to unravel some shared genetic etiology that could underlie the several 
similarities seen in phenotypes of the two conditions, such as age of onset, lifetime risk, 
suicide risk, gender distribution, and heritability estimates (122). Two shared phenotypic 
entities were selected for testing, affective and psychotic symptoms. In this combined 
analysis, all the previous diagnostic categories from the original scans were disregarded 
and the entire family material was recoded. Individuals diagnosed with affective or 
psychotic symptoms were coded as affected in the respective classes. The affective 
phenotype included major depressive disorder, dysthymic disorder, cyclothymic disorder 
as well as depressive disorder NOS. The psychotic phenotype included schizophrenia, 
schizophreniform disorder, schizoaffective disorder, bipolar I disorder with psychotic 
features, major depressive disorder with psychotic features, delusional disorder, shared 
psychotic disorder, brief psychotic disorder as well as psychotic disorder NOS. 
Therefore, only families that contained individuals with either affective or psychotic 
phenotypes were included in these analysis, resulting in a combined study sample of 352 
families for affective phenotype (309 affecteds) and psychotic phenotype (841 
affecteds). However, there was overlap between the families and individuals entered into 
the affective phenotype and psychotic phenotype groups. In the bipolar study sample all 
40 families entered into both affective and psychotic groups, altogether 113 individuals 
displayed symptoms from both diagnostic categories. In the schizophrenia study sample 
all 312 families entered into both affective and psychotic groups. In this sample set 158 
individuals displayed symptoms from both diagnostic categories (Table 7). In order to 
make the results of the combined analysis comparable with that of the original data, both 
BPD and SZ scans were re-analyzed including only those families that were informative 
for the combined analysis using broad DSM-IV diagnostic categories for BPD and SZ, 
respectively 6 (BPD: bipolar disorder type I, II and not otherwise specified (NOS), 
schizoaffective disorder of bipolar type, cyclothymic disorder or recurrent major 
depressive disorder, SZ: schizophrenia, schizoaffective disorder, included the DSM-IV 
diagnosis of bipolar disorder type I, II and NOS, schizoaffective disorder, 
schizophreniform disorder, delusional disorder, brief psychotic disorder or psychotic 
disorder NOS, as well as schizoid, schizotypal or paranoid personality disorder).  
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Table 7. 
Description of the study sample analyzed in the combined analysis 
Affective
phenotype 
Psychotic 
phenotype 
Bipolar disorder Families 40 40 
 Affected 128 123 
 Controls 203 208 
Schizophrenia Families 312 312 
 Affected 181 718 
 Controls 1681 1144 
Combined Families 352 352 
 Affected 309 841 
 Controls 1884 1352 
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4.2 Laboratory methods 
4.2.1 DNA extraction 
20-30ml of venomous blood was into ETDA tubes, and DNA was extracted according to 
a standard protocol (123). 
4.2.2 Genotyping 
All microsatellite markers in the studies were amplified using PCR. The fluorescently 
labeled PCR products were electrophoretically separated, either with an automated laser 
fluorescence DNA sequencer ABI 377 (Perkin-Elmer), using GENESCAN (version 2.1) 
fragment-analysis software, or with an LI-COR DNA 4200 Genetic Analyzer (LI-COR 
Biosciences). The alleles were identified using the GENOTYPER program (version 2.0; 
Perkin-Elmer) or genotyping software SAGA version 5.1 (LI-COR Biosciences). Two 
researchers checked independently the interpretation of alleles. The microsatellite 
markers were all di-, tri- or tetranucleotide repeats selected from the Marshfield Medical 
Research Foundation (Weber sets 6 and 9). The average intermarker interval in the 
genome-wide scan was ~ 7.7cM and the maximum 20 cM. Map positions were derived 
primarily from the Marshfield integrated map.  
4.2.3 Statistical methods 
In all studies the Mendelian inheritance of alleles in the pedigrees was confirmed prior to 
statistical analysis by the PedCheck program (124), as well as with SimWalk2 (125) and 
Mendel (126). Also all subjects were classified either as affected or unknown. By using 
this affected only (AO) model problems caused by incomplete penetrance of the disease 
and genetic ambiguity of the unaffected phenotype was circumvented. 
In the fine-mapping study of the X-chromosome (study I), the genotype data were 
analyzed using five hierarchical diagnostic categories: (I) bipolar disorder type I, (II) 
schizoaffective disorder; bipolar type, (III) bipolar disorder type II, bipolar NOS (not 
otherwise specified) and cyclothymia, (IV) recurrent major depressive disorder, (V) 
other mental disorders.  
In the parametric linkage analysis, both dominant and recessive modes of inheritance 
were tested. The required parameters set were as follows: the disease prevalence at 1%, 
disease-allele frequency 0.005 (dominant model) and 0.100 (recessive model), and 
allowing a phenocopy rate of 0.1%. We used the ANALYZE package, an accessory 
program to the LINKAGE package, to perform the two-point analysis. This package 
includes both programs used, MLINK and the HOMOG program, which tests the genetic 
heterogeneity between families.  
The affected sib pair (ASP) analysis was performed by the SIBPAIR program, and two 
different association analyses were performed by the haplotype relative risk (HRR) and 
transmission disequilibrium test (TDT). All the analyses, including the association 
analyses were performed using all the sibships in the pedigree structures. 
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Both nonparametric and parametric multipoint analyses were performed using only the 
diagnostic categories that gave the highest lod score in the two-point analyses by the 
GENEHUNTER program. 
In order to assess the significance of the linkage results a simulation study for the 
diagnostic categories I-II was carried out by the SIMULATE program.  
In the genome-wide scan study (study II), the data were analyzed using two different 
diagnostic categories enclosing the following DSM-IV diagnosis (I): BPD-I and SA-BP 
and (II): BPD-I, SA-BP, BPD-II, BPD-NOS, cyclothymic disorder and rMDD.  
Again, both dominant and recessive modes of inheritance were tested in the parametric 
analysis. In these analyses the penetrance of the disease allele was set at 0.9. The disease 
allele frequency was set at 1% and the phenocopy rate at 0.1% in the narrow diagnostic 
category (I), and for the broader spectrum a disease allele frequency of 5% and a 
phenocopy rate of 4.5% was used. In addition, one extended pedigree (family P101) was 
also analyzed separately from the other 40 families, in order to assess its influence on the 
lod scores due to its significant large size (n = 64). 
The analysis of the genome-wide scan was divided into two stages, in the first stage the 
preferred primary analyses methods were parametric (MLINK, HOMOG) and 
nonparametric (SIBPAIR) two-point linkage analyses.  
In the fine-mapping stage the association analyses and three-point analyses were 
performed for selected linked regions. The association analyses were performed using 
the PSEUDOMARKER program (23), which is a linkage analysis software for joint 
linkage and/or linkage disequilibrium analysis. We utilized LD given linkage statistics of 
the program, which calculates association free of the effect of linkage. The association 
results were corrected for multiple testing using the Dunn-Šidák correction (α’ = 1 – (1 - 
α)k ). The MLINK program was also used to perform three-point analysis. This analysis 
was not performed with flanking markers moving the disease across the map, because of 
the known propensity for false exclusions in that method. To avoid the known negative 
side effects of multipoint analysis, we performed a multipoint analysis in which the
markers were placed in a fixed order and in which the disease locus was allowed to vary 
outside the map of markers. Using this method, we found that meioses uninformative for 
some markers can be scored for nearby markers, thus allowing all meioses in all families 
to be scored in the analyses.
A simulation study estimating type I error rates was carried out by the SLINK program 
for the two peak markers, D4S1629 and D16S769. The exact same conditions under 
which the best lod scores were obtained for these two markers were reproduced in the 
simulation analysis eg. same family structures, statistical models and allele frequencies 
were used. The markers were simulated 10000 times under null-hypothesis (theta = 0.5), 
subsequently it was elucidated how many times the same or exceeding maximum LOD 
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scores were retrieved by analyzing these 10.000 replicates using ANALYZE program. 
The empirical P-values obtained were then Dunn-Šidák corrected. 
In the meta-analysis study (study III), a rank-based genome scan meta-analysis method 
(GSMA) was utilized (60, 127, 128). The linkage results attained from each group were 
maximized across the different transmission models for each marker.  And based on the 
GSMA method the genome was divided into 120 30-cM bins that were defined by 
markers from the Genethon map (CEPH-Geneton Integrated map). The average bin 
width according to the Marshfield map was 29.1 cM. Each marker from each study was 
placed within one of these bins, and for each study in a given analysis, the maximum 
linkage score or minimum P-value was selected within each bin and the bins were 
assigned a rank (Rstudy) in ascending order. The average rank (Ravg) for each bin was then 
computed across the study. Also a weighted analysis was performed taking in 
consideration the sample size in each study. Here, each R study value was multiplied by 
its study’s weight ( ?N[affected cases] ), divided by the mean of this value over all 
studies. Two pointwise P values were determined by permutation (500 permutations per 
analysis): PAvgRnk and Pord.
In the combined analysis (study IV), the two-point linkage analysis was performed using 
the MLINK program. For the genotyping data originating from the SZ genome-wide 
scan study a disease-allele frequency of 0.001 was used, assuming no phenocopies. For 
the genotyping data originating from the BPD genome-wide scan study a disease-allele 
frequency of 0.005 was used, allowing a phenocopy rate of 0.1%. The results presented 
are the summed lod scores maximized over recombination fraction in increments of 0.02. 
The conservative approximation of the population allele frequency from the individual 
study sample was used. To refrain from introducing false positive inflation of the linkage 
evidence due to different genetic background of the separate samples, the population 
allele frequencies were estimated separately for the two samples, linkage analysis 
performed separately and the lod scores subsequently added at every recombination 
fraction for the two samples. 
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5. Results and discussion 
5.1 Replication of the X-chromosomal linkage finding 
In an earlier study we repoted significant evidence of linkage (Zmax = 3.54) for BPD to 
chromosome Xq24-q27.1 in an extended pedigree from the late settlement region of the 
genetically isolated population of Finland. This particular family displayed a distinct X-
chromosomal haplotype covering a 19 cM wide region that co-segregated with BPD. In 
the present study our aim was two demensional, on one hand we wanted to replicate this 
linkage finding in a larger set of nuclear families. And on the other hand, we wanted to 
test if this particular pedigree showed evidence of linkage to other chromosomal regions 
in the genome. Since the extended family originated from an isolated region in Finland 
that overall presents a higher prevalence of BPD, we chose a nationwide replication 
sample in an attempt to evaluate if this X-chromosomal finding represented a more 
general genetic predisposion to BPD.  
In the first part of the study, we analyzed eight microsatellite markers scattered over the 
13cM wide critical linkage region on Xq24-q27 with the population-wide nuclear family 
samples (n = 40). However, since two new subjects of family P101 had been added and 
two diagnoses had changed in reassessment, the extended pedigree P101 was also re-
analyzed in the present study. In addition, new more robust statistical parameters were 
utilized in the present study in comparision to the previous study (age dependent liability 
classes versus affected only model). When applying of the new statistical parameters to 
the original family-setup of P101, the maximum lod score of 3.54 dropped to 2.17. When 
including the new individuals and the changed diagnosis into the equation a maximum 
lod score of 1.89 was achieved for the original peak marker (Table 8). When excluding 
family P101 from the analysis and only testing the 40 nuclear pedigrees, a maximum lod 
score of 1.34 was obtained, hence meeting the guidelines for replication of a linkage 
finding (Z ? 1.2) (Table 8). When testing the entire sample including all 41 families a 
maximum lod score of 2.78 was obtained shifting the linkage peak to the next marker 
telomericly located of the original linkage peak. In the present study the co-segreagting 
haplotype could again be seen in all individuals affected by bipolar disorder type I.  
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**Hypoxanthine Phosposyltransferase 
Theta (θ) indicates recombination fraction 
In the second phase of the study, we scanned the genome for any other potential linked 
regions for family P101. Although, these analyses showed that a gene predisposing this 
family to bipolar disorder is very likely located in this X-chromosomal region also 4q32 
showed signals of modest linkage.  
   
Figure 3. 
Shows the maximum two-point lod score results for family P101 for all the markers in 
the BPD genome-wide scan. 
Table 8. 
Here the maximum two-point lod score results under diagnostic category II for the 40 
new families (and for family P101) are presented. 
MARKER θ = 0.0 θ = 0.1 θ = 0.2  θ = 0.3 
DX737  - 19.52 (0.71) - 2.87 (0.45) - 0.60 (0.45)   0.05 (0.30) 
DXS1047  - 10.53 (1.84)   1.58 (1.44)   2.14 (1.02)   1.44 (0.61) 
DXS994  - 11.89 (1.89) - 0.25 (1.54)   0.90 (1.16)   0.84 (0.76) 
HPRT** - 16.26 (1.77) - 1.86 (1.41)   0.07 (1.04)   0.44 (0.65) 
DXS1062  - 16.93 (0.11) - 2.88 (0.08) - 0.80 (0.04) - 0.14 (0.02) 
DXS6854  - 13.73 (1.72) - 0.98 (1.41)   0.44 (1.06)   0.59 (0.69) 
DXS102  - 14.54 (0.07) - 3.05 (0.05) - 1.02 (0.03) - 0.29 (0.01) 
DXS984  - 15.24 (-1.97) - 3.01 (-1.17) - 0.90 (-0.60) - 0.20 (-0.27) 
Genome-wide scan: family P101
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In conclusion, only a fraction of the families provided any evidence of linkage to this 
region suggesting that a relatively rare gene predisposing to BPD is enriched in the 
extended family P101. The genome-wide scan for BPD predisposing loci in this large 
pedigree indicated that this particular X-chromosomal region provides the best evidence 
of linkage genome-wide, suggesting a X-chromosomal gene with a major role for the 
genetic predisposition of BPD in this family (Figure 3). 
5.2 Genome-wide scan in a nationwide BPD family sample 
We conducted a genome-wide scan with aim to identify loci predisposing to bipolar 
disorder by utilizing the benefits of an isolated population and a nationwide Finnish 
family-set. To our knowledge, this is one of the largest genome-wide scans targeted on 
narrowly diagnosed bipolar disorder. Furthermore, we have followed a strict family 
ascertainment strategy, e.g. by ascertaining the probands nationwide using criteria of an 
early age-of-onset (first bipolar episode under 31 years of age) and requiring two or more 
hospitalizations due to BPD-I or SA-BPD. We have thus made an effort to include more 
genetically loaded BPD cases in this study sample.  
A total of 27 markers showed a maximum two-point LOD score of 1.0, three of which 
produced a LOD score > 2.0 (4q32, 12q23 and Xq25), and one > 3.0 (16p12) (Table 9). 
Regions on 4q32, 12q23 and 16p12 were fine-mapped by including additional unaffected 
family members. One extended pedigree (family P101) was systematically analyzed 
separately from the remaining 40 families due to its significantly larger impact in 
statistical analyses. This family alone could exert a major influence on the linkage 
results, possible outweighing the contribution of all other families. Nonetheless, it did 
not seem to have a major effect on autosomal locus findings. This particular family P101 
was ascertained already decades ago and has ever since been the primary family included 
in our genetic studies. Through these previous studies significant evidence of linkage to 
Xq24-q27 was found. Family P101 was here included into the statistical analyses of the 
genome-wide scan, since multiple affected individuals provided significant linkage and 
phase information for putative additional loci. 
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Narrow diagnostic category = BPD-I and SA-BPD,  
Broad diagnostic category = BPD-I, SA-BPD, BPD-II, BPD-NOS, Cyclothymic Disorder, rMDD. 
Table 9. 
Show the markers in the genome-wide scan resulting in Zmax > 1.0 for the 40 
families and family P101 separetly.  
CHR cM 40 fam.  P101  
  Diagnostic  
category
Zmax Diagnostic 
category Zmax
Chr.1 175.62 Broad 1.0 Broad 1.0 
Chr.1 212.44 Broad 1.8 Broad 0.3 
Chr.1 215.17 Broad 1.8 Narrow 0.2 
Chr.3 102.64 Broad 0.8 Broad 0.8 
Chr.3 124.16 Broad 1.1 Broad 1.1 
Chr.3 134.64 Narrow 0.8 Narrow 1.0 
Chr.3 138.0 Broad 1.1 Broad 1.1 
Chr.4 157.99 Broad 2.4 Broad 2.6 
Chr.5 52.55 Broad 1.1 Narrow 1.4 
Chr.5 59.3 Broad 0.2 Narrow 1.2 
Chr.7 50.29 Narrow 1.4 Narrow 1.0 
Chr.8 26.43 Narrow 1.5 Narrow 1.5 
Chr.8 77.89 Broad 1.4 Broad 1.4 
Chr.8 164.47 Broad 1.6 Broad 1.6 
Chr.9 44.28 Narrow 1.3 Broad 1.2 
Chr.11 33.02 Broad 1.1 Broad 1.1 
Chr.11 131.26 Broad 1.0 Broad 1.0 
Chr.12 109.47 Broad 2.0 Broad 2.0 
Chr.14 40.68 Broad 1.3 Broad 1.1 
Chr.14 66.81 Broad 0.7 Broad 1.1 
Chr.14 105.53 Broad 1.6 Broad 1.1 
Chr.14 125.88 Narrow 1.0 Broad 1.1 
Chr.16 50.6 Narrow 3.4 Broad 2.5 
Chr.17 10.72 Broad 1.2 Broad 1.2 
Chr.X 82.07 Narrow 1.3 Narrow 1.3 
Chr.X 97.89 Broad 1.2 Broad 1.2 
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All three chromosomal regions that were fine-mapped gained further, eventhough 
modest support from the additional marker and subjects. The most significant two-point 
lod score of 3.4 was observed on 16p12 and the same linkage region obtaining a 
maximum three-point lod score of 2.7. Also modest support was found in the association 
analysis (P = 0.0680) (Table 10). Chromosome 4q32 obtained a lod score of 2.6, which 
was strengthened in the three-point analysis to a three-point lod score of 3.6. This region 
was also significant in the association analysis (P = 0.0319) (Table 10). Despite the large 
amount of linkage evidence between bipolar disorder and the chromosomal region 
12q24, we found no further support in the finemapping stage.  
Table 10. 
Maximum two-point linkage results from the fine-mapping stage and well as Dunn-
Šidák corrected association results.  
Chr Marker cM MOI* Diag.** Family
material  
Two-point 
lod score: 
Zmax(α)
*** 
Association 
test:
P-value 
4 D4S3049 155 ASP Narrow 40 fam. 0.9 0.031 
4 D4S1629 158 Dom Broad 41 fam. 2.6  0.983 
4 D4S1528 162 Rec Broad 40 fam. 1.9 0.968 
12 D12S1607 108 Dom Narrow 41 fam. 0.5  
(θ = 0.24) 
0.965 
12 PAH 109 ASP Broad 40/41 
fam. 
2.0 1.000 
12 D12S78 112 Dom Narrow 40 fam. 0.4  
(θ = 0.22) 
0.642 
16 D16S403 47 Dom Broad 40 fam. 0.4 0.068 
16 D16S769 51 Dom Narrow 40 fam. 3.4  
(θ = 0.22) 
0.999 
16 D16S3093 52 Dom Broad 40 fam. 0.8 0.759 
* Mode of Inheritance   ** Diagnostic category  *** Alpha (α) if maximum LOD score is obtained 
from analysis allowing for heterogeneity 
Family material included in the two point analyses; 41fam = all families, 40 = excluding family 
P101 from the analyses 
Mode of inheritance; ASP = Affected Sib-Pair, Dom = dominant mode of inheritance, Rec = 
recessive mode of inheritance. 
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In conclusion, two promising chromosomal regions on 4q32 and 16p12 emerged from 
our genome-wide scan study, both obtaining maximum lod scores exceeding 3.0. And 
since both regions have been implicated in several other independent studies from other 
populations, these findings meet the guideline given by Kruglyak et al. as statistically 
significant. It is encouraging to find similar genetic findings in the Finnish study sample, 
even though it represents an extreme population due to the isolation. Thus, this should 
stress the general significance of these results.  
5.3 Meta-analysis of worldwide genome-wide scans in BPD  
The inconsistency in the linkage results in BPD has long been evident. In large this is 
due to the small sample sizes utilized, thus in order to increase the power of linkage to 
produce a more generalized picture of genetic presidposition to BPD, meta-analysis are 
conducted. In these analyses, the results from different genome-wide scans are combined 
and analyzed in a combined fashion. Here, in this study 18 genome-wide scans 
conductede world-wide were analyzed together. The selected studies were consistent in 
that they achieved reasonably even marker coverage of the genome, used well-established 
linkage statistical methods, diagnosed mood disorders on the basis of modern diagnostic 
instruments and criteria, and included predominantly European-ancestry subjects. 
However, the studies did vary in sample size, evenness of marker spacing, the number of 
linkage analyses that were applied, community-based versus more ethnically 
homogeneous samples, and the typical size of pedigrees, hence also a weighted analyses 
were performed.  
Using the rank-based genome scan meta-analysis (GSMA) method, three different 
models were analyzed; a phenotypically very narrow model (Model 1), a narrow (Model 
2), and a braod model (Model 3). The overall results are summarized in Table 11.  
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Several clear patterns were seen in this study. First, and a bit surprisingly, a genomewide
level of significance (PAvgRnk) was not reached in any of the analysis. Levision and 
colleagues established criteria for linkage in the simulation studies they conducted that 
nevertheless were not met here. Reasons behind this could be several, for one the 
differential sample ascertainment strategies, diagnostic batteries, and linkage methods 
used might result in this outcome. Alternatively, linkage might be detected only in 
certain populations or subsets of pedigrees that will be masked by the background noice. 
Secondly, overlapping results with a previously meta-analysis conducted in BPD by 
Bardner and Gershon were hardly seen. Nonetheless, same study samples were not 
analysed, in addition different statistical methods as well as phenotypical models were 
utilized in conducting the meta-analysis. 
Third, the meta-analysis showed very little support for overlapping genetic susceptibility 
loci in BPD and schizophrenia. However this might change with the use of a larger BPD 
sample set, and a more selective phenotype focusing on subjects with overt psychotic 
symptoms as hallucinations or delusions, as well as with combined analyses of
schizophrenia and psychotic BPD data.
Overall, it seems like disease loci that have a high enough relative risk to be detected 
even this kind of large survey are rare in BPD. Instead, it seems more plausible that these 
results are the outcome of loci of modest effect producing inconsistent and weak 
evidence for linkage with variable peak locations. The loci with higher relative risks 
appear to only be detected in specific population- or even family sets, where the risk 
locus is enriched. In summary, the present study provided some support for the following 
chromosomal regions 14q, 9p-q, 10q, 18p-q, and 8q that could contain common loci that 
are weakly linked to BPD in the various populations. 
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5.4 Combined analysis of BPD and SZ; investigating psychotic and 
affective symptoms 
In this study our aim was to evaluate the existence of a common genetic predisposition 
for shared phenotypic entities in schizophrenia and bipolar disorder, which both 
represent prevalent psychiatric disorders with genetically complex backgrounds. The 
vast amount of overlap between the clinical features, familial aggregation and even 
observed genetic linkage peaks have led to speculation of common predisposing genetic 
factors among the two disorders. By combining two Finnish genome-wide scans in 
schizophrenia and bipolar disorder respectively, we were able to increase the sample size 
significantly and hence also the statistical power. This strategy enabled the detection of 
two loci showing significant evidence of linkage to affective symptoms on chromosome 
6p21 and psychotic symptoms on chromosome 5q14 respectively, that both went 
unnoticed in the original genome-wide scans.  
By testing for linkage of shared phenotypes of clinical relevance, we found evidence for 
linkage of affective and psychotic symptoms exceeding that obtained in either one of the 
original separate genome-wide scans for bipolar disorder or schizophrenia on a total of 
11 chromosomal regions. Many of these regions are supported by linkage studies in 
psychiatric disorders and should thus be considered good targets for further genetic 
studies. The strongest linkage finding, a maximum LOD score of 4.7 for affective 
symptoms was obtained on 6p21 in the immediate vicinity of Dysbindin, a gene 
previously found to be associated to schizophrenia. Another interesting finding was the 
linkage of psychotic symptoms to 5q14 (Zmax = 3.8). The results demonstrate the value of 
the analyses of shared trait components in study samples ascertained for related but 
separate diagnostic entities. This strategy enables analyses of larger samples; hence 
increasing the power to detect linkage that otherwise might be overlooked.  
In summary, 21 marker loci exceeded lod scores of 1.5 in the combined analysis for 
either affective or psychotic disorder. The linkage results are shown in Table 12, where 
also the lod scores obtained in the original genome-wide scan analysis for schizophrenia 
and bipolar disorder is presented for comparison. The results suggest that these genomic 
regions are likely to contain genes affecting the risk for broadly defined affective or 
psychotic disorder rather than for SZ and BPD (Table 13). Thus, this demonstrates the 
feasibility of combining genotypic data from studies originally ascertained for separate 
disorders that potentially have overlapping genetic backgrounds, and increasing sample 
size and, consequently, statistical power. 
58
Table 13. 
Summarizes the susceptibility loci for affective and psychotic phenotypes obtained in 
our combined analysis, along with the maximum lod scores (Zmax ≥ 2.0) achieved on 
that cytogenic band. 
Affective phenotype loci Psychotic phenotype loci 
6p24-21 (Zmax  = 1.8 and 4.7) 5q14 (Zmax = 3.8) 
4q32 (Zmax = 2.6) Xq27-q28 (Zmax = 2.5) 
1q31-q32 (Zmax = 2.6) 8q24 (Zmax = 2.2) 
5q11-q12 (Zmax = 2.1) 4p15 (Zmax = 2.0) 
Table 12. 
Shows the markers in the combined analysis that exceeded a maximum lod score of 1.5 
for either affective or psychotic symptoms in comparison to the linkage results obtained 
from the original BPD and SZ genome-wide scans. 
Marker 
(SZ) 
Marker 
(BPD) cM Chr. 
Aff. 
phen. 
(Zmax)
Psych.
phen. 
(Zmax )
BPD-
scan
(Zmax)
SZ-
scan
(Zmax)
D6S1017 D6S1017 63 6p21 4.7 0.1 0.0 0.5 
D5S428 D5S1725 98 5q14 0.2 3.8 0.1 0.0 
D4S1629 D4S1629 158 4q32 2.6 0.3 2.5 0.0 
D1S1660 D1S1660 212 1q31 2.6 0.4 1.7 0.5 
DXS1193 DXS1193 98 Xq28 0.1 2.5 0.6 0.0 
DXS1192 DXS8013 86 Xq27 1.5 2.5 0.4 1.0 
D8S263 D8S1128 140 8q24 0.7 2.2 0.3 0.4 
D5S647 D5S2500 69 5q11-12 2.1 2.0 0.2 3.5 
D4S2397  D4S2397 43 4p15 0.1 2.0 0.0 0.4 
D1S1723 D1S1723 215 1q32 1.9 0.3 0.9 1.0 
D20S103 D20S103 2 20p13 0.7 1.9 0.5 0.1 
D16S415 D16S753 58 16p11-12 0.2 1.9 0.1 0.6 
D16S539 D16S621 125 16q24 1.9 0.0 0.2 0.0 
D5S1501 D5S1501 85 5q14 0.3 1.8 0.2 0.4 
D6S1721 D6S1006 27 6p24 1.8 0.1 0.0 0.2 
D16S769 D16S769 51 16p12 1.3 1.8 2.9 0.7 
D9S930 D9S302 123 9q32 0.0 1.7 0.0 0.1 
D16S746 D16S3093 52 16p11-12 0.5 1.6 0.4 0.0 
D3S2465 D3S2465 112 3p12 1.6 0.1 0.0 0.0 
D3S2406 D3S2406 103 3p13 1.5 0.0 1.5 0.3 
D2S1391 D2S1391 186 2q32 0.0 1.5 0.0 0.3 
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6. Concluding Remarks and Future Prospects 
General observations can be made about the difficulties in identifying disease genes for 
psychiatric disorders like schizophrenia and bipolar disorder. Yet it appears that the 
unraveling of the genetic predispositions to schizophrenia is a step ahead of bipolar 
research. It seems like several factors contribute to this trend including the use of larger 
samples, a narrower phenotype, and more conservative and uniform data analysis in the 
schizophrenia studies. However, the most significant advantage in schizophrenia 
research is a more clear-cut and reliable phenotype presentation due to the non-cycling 
nature of the disorder, and in addition excellent endophenotypes exist for schizophrenia. 
The development of similar phenotypic traits or markers is critical in BPD since these 
may represent a more direct expression of underlying genes and thus be far more 
informative of the aggregate psychiatric phenotypes. Some of the endophenotypes that 
may underlie mood disorders include circadian rhythm, stress reactivity, and mood, 
sleep, and appetite regulation, however, more research needs to be conducted before the 
validity of these endophenotypes can be confirmed. However, endophenotypes like these 
could potentially be extended to animal models giving rise to powerful research tools by 
enabling biological validation tests in in vitro or transgenic animal model systems.   
For the foreseeable future, linkage studies will remain the preliminary effort for 
systematic molecular genetic research in BPD. Even though the results from linkage 
studies have been far less thriving than originally anticipated, rapid developments of the 
genotyping and gene-expression technologies are now enabling cheaper, faster and more 
precise massive high-throughput research. Nevertheless, the sample sizes to date are still 
too trivial to achieve the relevant statistical power needed to detect the underlying 
predisposing genotypes. Thus, it is of great importance that more future efforts to 
combine samples through methods such as meta-analysis or combined analysis are taken, 
especially since individual susceptibility genes are likely to confer only modest increases 
in risk for bipolar disorder and therefore making their detection even more challenging. 
Encouragingly, several chromosomal regions have repeatedly been implicated by 
independent groups from different populations suggesting that true linkage signals may 
have been uncovered. The identification of the actual disease-predisposing variant in the 
usually large regions is a challenge that requires a combination of genetic and biological 
strategies and hypothesis. For example the involvement of epigegenetic factors such as 
DNA methylation, histone deacetylation, chromatin modification, RNA interference, 
RNA editing and DNA rearrangement have long been proposed in BPD. And since 
epigenetic processes increase the complexity of genomic responses by allowing short-
term fine-tuning of the genome, and provide a mechanism for preserving information on 
environmental exposures, it is set to again emerge as an important avenue of research. 
Yet even the most successful genetic mapping experiments will never tell the whole 
pathophysiologic story, thus it must be further complemented with gene expression 
studies, studies in model organisms, and, ultimately, basic neurobiology. 
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